Compounds having certain oxime ether structures are disclosed in U. S.

Patent Nos. 5,194,662,5,292,759, and 6,063,956. The disclosed compounds provide control of a variety of fungal organisms. We have discovered a select group of such cyclopropyl oxime ethers containing specific substituted aryl and heterocyclic moieties which possess unexpectedly superior fungicidal properties when compared with the genus of compounds disclosed in the aforementioned patents.

The cyclopropyloxime ethers of the present invention have the Formula (I) wherein X is N or CH; Z is O, S, or NRs ; A is hydrogen, halo, cyano, (Cl-Cl2) alkyl, or (Cl-Cl2) alkoxy; R1 and R8 are independently hydrogen or (Cl-C4) alkyl ; R2 is hydrogen, (Cl-C4) alkyl, halo (Cl-C4) alkyl, (C3-C6) cycloalkyl, halo (C3- C6) cycloalkyl, (C2-C4) alkenyl, halo (C2-C4) alkenyl, (C2-C4) alkynyl, halo (C2-C4) alkynyl, or cyano; R3 is hydrogen, (C1- C4)alkyl, halo (Cl-C4) alkyl, (C3-C6) cycloalkyl, halo (C3- C6) cycloalkyl, (C2-C4) alkenyl, halo (C2- C4) alkenyl, (C2-C4) alkynyl, or halo (C2- C4) alkynyl ; R4 and R5 are independently hydrogen, (C1-C4) alkyl, halo (Cl- C4) alkyl, (C3-C6) cycloalkyl, halo (C3-C6) cycloalkyl, (C2-C4) alkenyl, halo (C2- C4) alkenyl, (C2-C4) alkynyl, halo (C2-C4) alkynyl, halo, cyano, or (Ci- C4) alkoxycarbonyl ; and wherein A) R7 is aryl or heterocyclic ring wherein the aryl or heterocyclic ring is substituted with from 2 to 5 substituents and wherein the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring are both substituted and R6 is hydrogen, (Cl-C4) alkyl, halo (Cl- C4) alkyl, (C3-C6) cycloalkyl, halo (C3-C6) cycloalkyl, (C2-C4) alkenyl, halo (C2- C4) alkenyl, (C2-C4) alkynyl, halo (C2 - C4) alkynyl, halo, cyano, or (Cl-C4) alkoxycarbonyl ; or B) R7 is an aryl or heterocyclic ring wherein the aryl or heterocyclic ring is unsubstituted or substituted from 1 to 4 substituents wherein at least one of the positions on the aryl or heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen and R6 is selected from the group consisting of (Ci-C4) alkyl, halo (Cl-C4) alkyl, (C3-C6) cycloalkyl, halo (C3- C6) cycloalkyl, (C2-C4) alkenyl, halo (C2- C4) alkenyl, (C2-C4) alkynyl, halo (C2- C4) alkynyl, halo, cyano, or (Cl-C4) alkoxycarbonyl ; and their salts, complexes, enantiomorphs, stereoisomers; and mixtures thereof.

The biological activity of compounds of Formula I is greatly influenced by the interaction between the R6 and R7 groups, which are attached to the same carbon on the cyclopropyl ring, and, more specifically, by the number, type, and configuration of substituents on the aryl or heteroaryl R7, particularly those in the ortho position to the bond between the R7 group and the cyclopropyl ring, while taking into account whether the R6 group is a hydrogen or a different group.

The aforementioned alkyl, alkenyl, alkynyl and (C3-C6) cycloalkyl groups may be optionally and independently substituted with up to three substituents selected from nitro, halomethyl, (Cl-C4) alkoxycarbonyl, and cyano.

Unless otherwise specified herein, the term alkyl includes both branched and straight chain alkyl groups from 1 to 4 carbon atoms. Typical alkyl groups are methyl, ethyl, n-propyl, iso-propyl, n-butyl, sec-butyl, isobutyl, t-butyl, n- pentyl, isopentyl, n-hexyl, n-heptyl, isooctyl, nonyl, decyl, undecyl, dodecyl and the like. The term haloalkyl refers to an alkyl group substituted with from 1 to 3 halogens.

Unless otherwise specified herein, the term alkenyl refers to an ethylenically unsaturated hydrocarbon group, straight or branched, having a chain length of from 2 to 4 carbon atoms and 1 ethylenic bonds. The term haloalkenyl refers to an alkenyl group substituted with from 1 to 3 halogen atoms. The term alkynyl refers to an unsaturated hydrocarbon group, straight or branched, having a chain length of from 2 to 4 carbon atoms and 1 acetylenic bonds.

Unless otherwise specified herein, the term aryl includes phenyl and naphthyl which maybe substituted with up to five substituents independently selected from halogen, cyano, nitro, trihalomethyl, trihalomethoxy, phenyl, phenoxy, (C1-C4) alkyl, (C3-C6) cycloalkyl, (C2-C4) alkenyl, (Cl-C4) alkoxy, (C1- C4) alkylthio, (Cl-C4) alkylsulfoxide, halo (C1-Calkyl, halo (Ci-C4) alkoxy, halo (C3- C6) cycloalkyl, halo (C2-C4) alkenyl, or (Cl-C4) alkoxycarbonyl. Typical phenyl substituents, wherein at least one of the positions on the phenyl ring adjacent to the bond to the cyclopropyl ring is substituted with hydrogen include but are not limited to 2-chloro, 3-chloro, 4-chloro, 2-fluoro, 3-fluoro, 4-fluoro, 2-bromo, 3- bromo, 4-bromo, 2-methyl, 3-methyl, 4-methyl, 2-trifluoromethyl, 3- trifluoromethyl, 4-trifluoromethyl, 2-methoxy, 3-methoxy, 4-methoxy, 2- trifluoromethoxy, 3-trifluoromethoxy, 4-trifluoromethoxy, 2-cyano, 3-cyano, 4- cyano, 2,3-dichloro, 2,3-difluoro, 2,3-dibromo, 2,3-dimethyl, 2,3-dimethoxy, 2,3- bis (trifluoromethyl), 2,3bis- (trifluoromethoxy), 2,4-difluoro, 2,4-dichloro, 2,4- dibromo, 2,4-dimethyl, 2,4-dimethoxy, 2,4-bis (trifluoromethyl), 2,4- bis (trifluoromethoxy), 2,5-difluoro, 2,5-dichloro, 2,5-dibromo, 2,5-dimethyl, 2,5- dimethoxy, 2,5-bis (trifluoromethyl), 2,5-bis- (trifluoromethoxy), 3,4-difluoro, 3,4- dichloro, 3,4-dibromo, 3,4-dimethyl, 3,4-dimethoxy, 3,4-bis (trifluoromethyl), 3,4- bis (trifluoromethoxy), 3,5-difluoro, 3,5-dichloro, 3,5-dibromo, 3,5-dimethyl, 3,5- bis (trifluoromethyl), 3,5-bis (trifluoro-methoxy), 2,3,4-trifluoro, 2,3,4-trichloro, 2,3,4-tribromo, 2,3,4-trimethyl, 2,3,4-trimethoxy, 2,3,4-tris (trifluoromethyl), 2,3,4-tris (trifluoromethoxy), 2,3,5-trifluoro, 2,3,5-trichloro, 2,3,5-tribromo, 2,3,5- trimethyl, 2,3,5-tris (trifluoromethyl), 2,3,5-tris (trifluoromethoxy), 2,4,5-trifluoro, 2,4,5-trichloro, 2,4,5-tribromo, 2,4,5-trimethyl, 2,4,5-trimethoxy, 2,4,5- tris (trifluoromethyl), 2,4,5-tris (trifluoromethoxy), 3,4,5-trifluoro, 3,4,5-trichloro, 3,4,5-tribromo, 3,4,5-trimethyl, 3,4,5-trimethoxy, 3,4,5-tris (trifluoromethyl), 3,4,5-tris (trifluoromethoxy), 2,3,4,5-tetrafluoro, 2,3,4,5-tetrachloro, 2,3,4,5- tetrabromo, 2,3,4,5-tetramethyl, 2,3,4,5-tetramethoxy, 2,3,4,5- tetra (trifluoromethyl), and 2,3,4,5-tetra (tetrafluoromethoxy.

Typical phenyl substituents, where both positions on the phenyl ring adjacent to the bond to the cyclopropyl rings are substituted include but are not limited to 2,6-dichloro, 2,3,6-trichloro, 2,4,6-trichloro, 2,6-difluoro, 2,3,6-trifluoro, 2,4,6-trifluoro, 2,6-dibromo, 2,3,6-tribromo, 2,4,6-tribromo 2,3,4,6-tetrachloro, 2,3,5,6-tetrachloro, 2,3,4,5,6-pentachloro, 2,3,4,6-tetrabromo, 2,3,5,6-tetrabromo, 2,3,4,5,6-pentabromo, 2,3,4,6-tetrafluoro, 2,3,5,6-tetrafluoro, 2,3,4,5,6- pentafluoro, 2,6-dimethyl, 2,3,6-trimethyl, 2,4,6-trimethyl, 2,6-dimethoxy, 2,3,6- trimethoxy, 2, 4,6-trimethoxy, 2,6-diethoxy, 2,3,6-triethoxy, 2,4,6-triethoxy, 2,3,4,6-tetramethyl, 2,3,5,6-tetramethyl, 2,3,4,5,6-pentamethyl, 2,3,4,6- tetramethoxy, 2,3,5,6-tetramethoxy, 2,3,4,5,6-pentamethoxy, 2,3,4,6- tetraethoxy, 2,3,5,6-tetraethoxy, 2,3,4,5,6-pentaethoxy, 2,6-dicyano, 2,3,6- tricyano, 2,4,6-tricyano, 2,6-dinitro, 2,6-diphenyl, 2,6-diphenoxy, 2,6-dibenzyl, 2,6-bis (trifluoromethyl), 2,3,6-tris (trifluoromethyl), 2,4,6-tris- (trifluoro-methyl), 2,3,4,6-tetra (trifluoromethyl), 2,3,5,6-tetra (trifluoromethyl), 2,3,4,5,6- penta (trifluoromethyl), 2,6-bis- (trifluoromethoxy), 2,3,6-tris (trifluoromethoxy), 2,4,6-tris (trifluoromethoxy), 2,3,4,5-tetra (trifluoromethoxy), 2,3,4,6-tetra- (trifluoro-methoxy), 2,3,5,6-tetra (trifluoromethoxy), 2,3,4,5,6- penta (trifluoromethoxy), 2-bromo-6-chloro, 2-bromo-6-fluoro, 2-bromo-6- (trifluoromethyl), 2-bromo-6-methyl, 2-bromo-6-methoxy, 2-bromo-6- (trifluoromethoxy), 2-bromo-6-cyano, 2-chloro-6-fluoro, 2-chloro-6- (trifluoromethyl), 2-chloro-6-methyl, 2-chloro-6-methoxy, 2-chloro-6- trifluoromethoxy), 2-chloro-6-cyano, 2-fluoro-6- (trifluoromethyl), 2-fluoro-6- methyl, 2-fluoro-6-methoxy, 2-fluoro-6- (trifluoromethoxy), 6-cyano-2-fluoro, 2- methyl-6- (trifluoromethyl), 6-methoxy-2-methyl, 2-methyl-6- (trifluoromethoxy), 6-cyano-2-methyl, 3,6-dichoro-2-fluoro, 3-chloro-2,6-difluoro, 4-chloro-2,6- difluoro, 2-bromo-3,6-dichoro, 2,3-dibromo-6-chloro, 3-chloro-2,6-dibromo, 2,6- dichloro-3-fluoro, 2,3-dichloro-6-fluoro, 2-chloro-3, 6-difluoro, 3-bromo-2,6- dichloro, 3-bromo-2,6-fluoro, 3-bromo-6-chloro-2-fluoro, 2-bromo-5-chloro-6- fluoro, 2,6-dibromo-3-fluoro, 2,5-dibromo-6-fluoro, 2,4-dichloro-6-fluoro, 2,6- chloro-4-fluoro, 2,4,-dichloro-6-bromo, 2,6-dichloro-4-bromo, 2,4-difluoro-6-chloro, 2,4-difluoro-6-bromo, 2,6-difluoro-4-bromo, 2,4-dibromo-6-fluoro, 2,4-dibromo-6- chloro, 2,6-dibromo-4-chloro, 2,6-dibromo-4-fluoro, 2,4-dichloro-6-methyl, 2,6- dichloro-4-methyl, 2-chloro-4,6-dimethyl, 4-chloro-2,6-dimethyl, 2,4-difluoro-6- methyl, 2,6-difluoro-4-methyl, 2-fluoro-4,6-dimethyl, 4-fluoro-2, 6-dimethyl, 2,4- dibromo-6-methyl, 2,6-dibromo-4-methyl, 2-bromo-4,6-dimethyl, 4-bromo-2,6- dimethyl, 2,4-dichloro-6-methoxy, 2,6-dichloro-4-methoxy, 2-chloro-4,6- dimethoxy, 4-chloro-2,6-dimethoxy, 2,4-difluoro-6-methoxy, 2,6-difluoro-4- methoxy-, 2-fluoro-4, 6-dimethoxy, 4-fluoro-2,6-dimethoxy, 2,4-dibromo-6- methoxy, 2,6-dibromo-4-methoxy, 4-bromo-2,6-dimethoxy, 4-bromo-2,6- dimethoxy, 2,4-dichloro-6- (trifluoromethyl), 2,6-dichloro-4- (trifluoromethyl), 2- chloro-4,6-bis (trifluoromethyl), 4-chloro-2,6-bis (trifluoromethyl), 2,4-difluoro-6- (trifluoromethyl), 2,6-difluoro-4- (trifluoromethyl), 2-fluoro-4,6- bis (trifluoromethyl), 4-fluoro-2, 6-bis (trifluoromethyl), 2,4-dibromo-6- (trifluoromethyl), 2,6-dibromo-4- (trifluoromethyl), 2-bromo-4,6- bis (trifluoromethyl), 4-bromo-2,6-bis (trifluoromethyl), 2-chloro-4,6- bis (trifluoromethoxy), 4-chloro-2,6-bis (trifluoromethoxy), 2,4-difluoro-6- (trifluoromethoxy), 2,6-difluoro-4- (trifluoromethoxy), 2-fluoro-4,6-bis (trifluoro- methoxy), 4-fluoro-2, 6-bis (trifluoromethoxy), 2,4-dibromo-6- (trifluoromethoxy), 2,6-dibromo-4- (trifluoromethoxy), 2-bromo-4,6-bis (trifluoromethoxy), 4-bromo- 2,6-bis (trifluoromethoxy), 4,6-dichloro-2-nitro, 4,6-dibromo-2-nitro, 4,6-difluoro- 2-nitro, 2,6-dichloro-4-nitro, 2-bromo-3,4,6-trichloro, 6-fluoro-2,4,5-trichloro, 6- chloro-2,4,5-tribromo, 6-fluoro-2,4,5-tribromo, 2-bromo-3,4,6-trifluoro, 2-chloro- 3,4,6-trifluoro, 6-methyl-2,4,5-trichloro, 6-methyl-2,4,5-tribromo, 6-methyl-2,4,5- trifluoro, 6- (trifluoromethyl)-2, 4,5-trichloro, 6- (trifluoromethyl)-2, 4,5-tribromo, 2- (trifluoro-methyl)-3, 4,6-trifluoro, 6- (trifluoromethoxy)-2, 4,5-tribromo, 2- (trifluoromethoxy)-3,4,6-trifluoro, 6- (trifluoromethoxy)-2, 4,5-trichloro, 2-bromo- 3,5,6-trichloro, 6-fluoro-2,3,5-trichloro, 6-chloro-2,3,5-tribromo, 6-fluoro-2,3,5- tribromo, 2-bromo-3,5,6-trifluoro, 2-chloro-3,5,6-trifluoro, 6-methyl-2,3,5- trichloro, 6-methyl-2,3,5-tribromo, 2-methyl-3,5,6-trifluoro, 6- (trifluoromethyl)- 2,3,5-trichloro, 6- (trifluoro-methyl)-2, 3,5-tribromo, 2- (trifluoromethyl)-3, 5,6- trifluoro, 2- (trifluoromethoxy)-3,5,6-trichloro, 6- (trifluoromethoxy)-2,3,5- tribromo, 2- (trifluoromethoxy)-3, 5,6-trifluoro, 4-bromo-2,3,5,6-tetrachloro, 4- fluoro-2, 3,5,6-tetrachloro, 4-chloro-2,3,5,6-tetrabromo-, 4-fluoro-2,3,5,6- tetrabromo, 4-chloro-2,3,5,6-tetrafluoro, 4-bromo-2,3,5,6-tetrafluoro, 2-bromo- 3,4,5,6-tetrachloro, 6-fluoro-2,3,4,5-tetrachloro-, 2-chloro-3,4,5,6-tetrafluoro, 2- bromo-3,4,5,6-tetrafluoro, 2-chloro-3,4,5,6-tetrabromo, 2-fluoro-3, 4,5,6- tetrabromo, 4-methyl-2,3,5,6-tetrachloro, 4-methyl-2,3,5,6-tetrabromo, 4-methyl- 2,3,5,6-tetrafluoro, 2,3,5,6-tetrachloro-4- (trifluoromethyl), 2,3,5,6-tetrabromo-4- (trifluoromethyl), 2,3,5,6-tetrafluoro-4- (trifluoromethyl), 2,3,5,6-tetrachloro-4- (trifluoromethoxy), 2,3,5,6-tetrabromo-4- (trifluoromethoxy, 2,3,5,6-tetrafluoro-4- (trifluoromethoxy), 6-methyl-2, 3,4,5-tetrachloro, 6-methyl-2,3,4,5-tetrabromo, 2- methyl-3,4,5,6-tetrafluoro, 2,3,4,5-tetrachloro-6- (trifluoromethyl), 2,3,4,5- tetrabromo-6- (trifluoromethyl), 3,4,5,6-tetrafluoro-2- (trifluoromethyl), 2,3,4,5- tetrachloro-6- (trifluoromethoxy), 2,3,4,5-tetrabromo-6- (trifluoromethoxy), and 3,4,5,6-tetrafluoro2- (trifluoromethoxy).

The term heterocyclic refers to a substituted 6 membered unsaturated ring selected from 3-or 4-pyridinyl, 5-pyrimidinyl, 3-pyridazinyl or a 5 membered unsaturated ring selected from 3-thienyl, 3-furyl, 3-pyrrolyl, 4- isoxazolyl, 4-isothiazolyl or 4-pyrazolyl wherein both the positions on the heterocyclic ring adjacent to the bond to the cyclopropyl ring are substituted and the ring is substituted with from 2 to 4 substituents independently selected from (Cl-C4) alkyl, (C3-C6) cycloalkyl, trihalomethyl, trihalomethoxy, halogen, cyano, (C1-C4) alkoxycarbonyl, nitro, phenyl, and phenoxy. The term heterocyclic also refers to a substituted or unsubstituted 6 membered unsaturated ring containing one, two or three heteroatoms, preferably one, two or three heteroatoms independently selected from oxygen, nitrogen, and sulfur or a 5 membered unsaturated ring containing one, two or three heteroatoms, preferably one or two heteroatoms independently selected from oxygen, nitrogen, and sulfur wherein the heterocyclic ring is unsubstituted or is substituted with from 1 to 3 substituents wherein at least one of the positions of the heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen substituent. Examples of heterocycles include but are not limited to 2-, 3-or 4-pyridinyl, pyrazinyl, 4-, or 5-pyrimidinyl, pyridazinyl, pyrazole, imidazolyl, 2 or 3-thienyl, 2 or 3-furyl, 3-pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, oxadiazolyl, and thiadiazolyl. These rings may be optionally substituted with up from 1 to 3 substituents independently selected from (C1-C4) alkyl, (C3-C7) cycloalkyl, trihalomethyl, halogen, cyano, (C1-C4) alkoxycarbonyl, nitro, phenyl, and phenoxy.

Halogen or halo includes iodo, fluoro, bromo and chloro moieties.

The compounds of the general Formula I may be obtained in preparation as E/Z isomeric mixtures. These isomers can be separated into individual components by conventional means. The substituted cyclopropanes of Formula I may be obtained in preparation as cis and trans isomeric mixtures which can also be separated into individual components by conventional means. Both the individual isomeric compounds as well as mixtures thereof form subjects of the invention and can be used as fungicides and insecticides.

One preferred embodiment of this invention includes the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A, R3, R4, and R5 are each hydrogen; Ri and R2 are CH3 ; R7 is 2,6- dichlorophenyl or 2,6-difluorophenyl; and R6 is hydrogen.

Another preferred embodiment of this invention includes the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A, R3, R4, and R5 are each hydrogen; R1 and R2 are CH3 ; R7 is 2,6- dichlorophenyl or 2,6-difluorophenyl; and R6 is halo, (C1-C4) alkyl, halo (C1- C4) alkyl, cyclopropyl, halocyclopropyl, (C2-C4) alkenyl, halo (C2-C4) alkenyl, (C2- C4) alkynyl, or halo (C2-C4) alkynyl.

Another preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; R1 and R2 are independently (C1-C4) alkyl; R3, R4, and R5 are hydrogen; R7 is phenyl other than 2,6-dichlorophenyl or 2,6-difluorophenyl such that the positions on the phenyl ring adjacent to the bond to the cyclopropyl rings are both substituted, and R6 is selected from hydrogen, halo, (Cl-C4) alkyl, halo (C1-C4) alkyl, cyclopropyl, halocyclopropyl, (C2-C4) alkenyl, halo (C2-C4) alkenyl, (C2-C4) alkynyl, and halo (C2-C4) alkynyl.

A more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; Rl and R2 are independently (Ci-C4) alkyl; R3, R4 and R5 are hydrogen; R6 is hydrogen; and R7 is 2,3,6-trisubstitutedphenyl, 2,4,6- trisubstitutedphenyl, 2,3,4,6-tetrasubstitutedphenyl, 2,3,5,6-tetrasubstituted, or 2,3,4,5,6-pentasubstitutedphenyl.

An even more preferred embodiment of this invention are the compounds, enantiomorphs, salts and complexes of Formula I wherein X is N; Z is NH; A is hydrogen; R1 and R2 are CH3 ; R3, R4 and R5 are hydrogen; R6 is hydrogen; and R7 is 2,3,6-trihalophenyl, 2,4,6-trihalophenyl, 2,3,4,6-tetrahalophenyl, 2,3,5,6- tetrahalophenyl, or 2,3,4,5,6-pentahalophenyl.

Still another preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is CH or N; Z is O or NH; A is hydrogen; Ri and R2 are independently (Cl-C4) alkyl; R3, R4 and R5 are hydrogen; R7 is a substituted or unsubstituted phenyl or heterocyclic wherein at least one of the positions on the phenyl or heterocyclic ring adjacent to the bond to the cyclopropyl ring is a hydrogen substituent; and R6 is (C1-C4) alkyl, halo (Ci- C4) alkyl, cyclopropyl, halocyclopropyl, (C2-C4) alkenyl, halo (C2-C4) alkenyl, (C2- C4) alkynyl, halo (C2-C4) alkynyl, halo or cyano.

Another more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula I wherein X is N; Z is O or NH; A is hydrogen; Ri and R2 is (CH3) ; R3, R4 and R5 are hydrogen; R7 is phenyl, 2- substitutedphenyl, 3-substitutedphenyl, 4-substitutedphenyl, 2,3- disubstitutedphenyl 2,4-disubstitutedphenyl, 2,5-disubstitutedphenyl, 3,4- disubstitutedphenyl, 3,5-disubstituted, 2,3,4-trisubstitutedphenyl, 2,3,5- trisubstitutedphenyl, 2,4,5-trisubstitutedphenyl, 3,4,5-trisubstitutedphenyl, or 2,3,4,5-tetrasubstitutedphenyl; and R6 is halo, cyano, (Cl-C4) alkyl, or halo (Cl- C4) alkyl.

A second even more preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula II wherein R7 is phenyl, 2-halophenyl, 3-halophenyl, 4-halophenyl, 2,3-dihalophenyl 2,4- dihalophenyl, 2,5-dihalophenyl, 3,4-dihalophenyl, 3,5-dihalophenyl, 2,3,4- trihalophenyl, 2,3,5-trihalophenyl, 2,4,5-trihalophenyl, 3,4,5-trihalophenyl, or 2,3,4,5-tetrahalophenyl, and RG is (C1-C4) alkyl.

A most preferred embodiment of this invention is the compounds, enantiomorphs, salts and complexes of Formula II wherein R7 is phenyl, 2- chlorophenyl, 3-chlorophenyl, or 4-chlorophenyl, 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,4-dichlorophenyl, 2,4-difluorophenyl, 2-chloro-4-fluorophenyl, 2-fluoro-4-chlorophenyl, and R6 is CH3.

Typical compounds of Formula I encompassed by the present invention wherein A, R3, R4, and R5 are hydrogen; X is CH and Z is O ; and R1 is methyl include those compounds presented in Table 1 of Formula III where R2, R6, and R7 are defined in Table 1. As used in Tables 1 to 12, Ph is phenyl.

Formula III Table 1 Comp R2 R6 R7 1.1HCH, Ph 1.2 H CHq 4-Cl (Ph) 1.3HCH, 4-Br (Ph) 1. 4 H CH3 4-F (Ph) 1. 5 H CH3 4-OCH3 (Ph) 1.6 H CH2 4-CF3 (Ph) 1.7 H CHq 4-NO2 (Ph) 1.8 H CHq 2,4-Cl (Ph) 1.9 H CHq 2,4-F (Ph) 1. 10 H CH3 3,4-F (Ph) 1. 11 CH3 CH3 Ph 1. 12 CH3 CH3 2-Cl (Ph) 1. 13 CH3 CH3 3-Cl (Ph) 1. 14 CH3 CH3 4-Cl (Ph) 1. 15 CH3 CH3 2-Br (Ph) 1. 16 CH3 CH3 3-Br (Ph) 1. 17 CH3 CH3 4-Br (Ph) 1. 18 CH3 CH3 2-F (Ph) 1. 19 CH3 CH3 3-F (Ph) 1. 20 CH3 CH3 4-F (Ph) 1. 21 CH3 CH3 2-OCH3 (Ph) 1. 22 CH3 CH3 3-OCH3 (Ph) 1. 23 CH3 CH3 4-OCH3 (Ph) 1. 24 CH3 CH3 2-CH3 (Ph) 1. 25 CH3 CH3 3-CH3 (Ph) 1. 26 CH3 CH3 4-CH3 (Ph) 1.27 CH3 CH3 2-CF3 (Ph) 1. 28 CH3 CH3 3-CF3 (Ph) 1. 29 CH3 CH3 4-CF3 (Ph) 1. 30 CH3 CH3 2-NO2 (Ph) 1. 31 CH3 CH3 3-NO2 (Ph) 1. 32 CH3 CH3 4-NO2 (Ph) 1.33 CH3 CH3 2,3-Cl (Ph) 1. 34 CH3 CH3 2,4-Cl (Ph) 1. 35 CHq CHq 2,5-Cl (Ph) 1. 36 CH3 CH3 3,4-Cl (Ph) 1. 37 CH3 CH3 3,5-Cl (Ph) 1. 38 CH3 CH3 2,3,5-Cl (Ph) 1. 39 CH3 CH3 2,3-F (Ph) 1. 40 CH3 CH3 2,4-F (Ph) 1. 41 CH3 CH3 2,5-F (Ph) 1. 42 CH3 CH3 3,4-F (Ph) 1. 43 CH3 CH3 3,5-F (Ph) 1. 44 CH3 CH3 2,4,5-F (Ph) 1.45 CH3 CH3 2,4,5-Cl (Ph) 1. 46 CH3 CH3 3, 4,5-Cl (Ph) 1.47 CH3 CH3 2,3,4,5-Cl (Ph) 1.48 CH3 CH3 2,3,5-F (Ph) 1.49 CH3 CH3 3,4,5-F (Ph) 1. 50 CH3 CH3 2, 3,4,5-F (Ph) 1. 51 C2H5 CH3 Ph 1. 52 C2H5 CH3 2-Cl (Ph) 1. 53 C2H5 CH3 3-Cl (Ph) 1. 54 C2H5 CH3 4-Cl (Ph) 1.55 C2Hs CH2 4-Br (Ph) 1. 56 C2H5 CH3 4-F (Ph) 1.57 C2H5 CH3 4-OCH3 (Ph) 1.58 C2H5 CH3 4-CH3(Ph) 1. 59 C2H5 CH3 4-NO2 (Ph) 1. 60 C2H5 CH3 2,4-Cl (Ph) 1. 61 C2H5 CH3 2,4-F (Ph) 1. 62 n-C3H7 CH3 Ph 1. 63 n-C3H7 CH3 2-Cl (Ph) 1. 64 n-C3H7 CH3 3-Cl (Ph) 1. 65 n-C3H7 CH3 4-Cl (Ph) 1. 66 n-C3H7 CH3 4-F (Ph) 1. 67 n-C3H7 CH3 3-OCH3 (Ph) 1.68 n-C3H7 CH2 4-OCH3 (Ph) 1. 69 n-C3H7 CH3 4-CH3 (Ph) 1.70 n-C3H7 CH2 4-NO2 (Ph) 1.71 n-C3H7 CH2 2,4-Cl (Ph) 1. 72 n-C3H7 CH3 2,4-F (Ph) 1.73 iso-C3H7 CH2 Ph 1. 74 iso-C3H7 CH3 2-Cl (Ph) 1.75 iso-C3H7 CHq 3-Cl (Ph) 1. 76 iso-C3H7 CH3 4-Cl (Ph) 1.77 iso-C3H7 CHq 4-Br (Ph) 1.78 iso-C3H7 CHq 4-F (Ph) 1.79 iso-C3H7 CHq 4-OCH3 (Ph) 1.80 iso-C3H7 CHq 4-CH3 (Ph) 1. 81 iso-C3H7 CH3 4-NO2 (Ph) 1. 82 iso-C3H7 CH3 2,4-Cl (Ph) 1. 83 iso-C3H7 CH3 2, 4-F (Ph) 1. 84 n-C4H9 CH3 Ph 1. 85 n-C4H9 CH3 2-Cl (Ph) 1. 86 -C4H9 CH3 3-Cl (Ph) 1. 87 n-C4H9 CH3 4-Cl (Ph) 1. 88 n-C4H9 CH3 4-Br (Ph) 1.89 n-C4Hs CH3 4-F (Ph) 1. 90 n-C4H9 CH3 4-OCH3 (Ph) 1. 91 n-C4H9 CH3 4-CH3 (Ph) 1.92n-C4H9CH34-N02 (Ph) 1. 93 n-C4H9 CH3 2, 4-Cl (Ph) 1. 94 n-C4H9 CH3 2, 4-F (Ph) 1. 95 iso-C4H9 CH3 Ph 1.96iso-C4H9CHs2-Cl (Ph) 1. 97 iso-C4H9 CH3 3-Cl (Ph) 1. 98 iso-C4H9 CH3 4-Cl (Ph) 1.99 iso-C4Hs CHs 4-F (Ph) 1. 100 iso-C4H9 CH3 2-OCH3 (Ph) 1.101 iso-C4Hs CH3 3-OCH3 (Ph) 1. 102 iso-C4H9 CH3 4-OCH3 (Ph) 1. 103 iso-C4H9 CH3 4-CH3 (Ph) 1.104iso-C4H9CH32, 4-Cl (Ph) 1. 105 iso-C4H9 CH3 2, 4-F (Ph) 1.106 cyclopropyl CH3 Ph 1. 107 cyclopropyl CH3 2-Cl (Ph) 1.108 cyclopropyl CH3 3-Cl (Ph) 1. 109 cyclopropyl CH3 4-Cl (Ph) 1. 110 cyclopropyl CH3 4-F (Ph) 1. 111 cyclopropyl CH3 3-OCH3 (Ph) 1. 112 cyclopropyl CH3 4-OCH3 (Ph) 1. 113 cyclopropyl CH3 4-CH3 (Ph) 1. 114 cyclopropyl CH3 4-NO2 (Ph) 1.115 cyclopropyl CH3 2,4-Cl (Ph) 1.116 cyclopropyl CH3 2, 4-F (Ph) 1. 117 1-CH3-cyclopropyl CH3 Ph 1. 118 1-CH3-cyclopropyl CH3 2-Cl (Ph) 1. 119 1-CH3-cyclopropyl CH3 3-Cl (Ph) 1. 120 1-CH3-cyclopropyl CH3 4-Cl (Ph) 1. 121 1-CH3-cyclopropyl CH3 2-Br (Ph) 1.122 CN CH3 Ph 1. 123 CN CH3 2-Cl (Ph) 1. 124 CN CH3 3-Cl (Ph) 1.125CNCH34-Cl (Ph) 1.126 CN CH3 2-Br (Ph) 1. 127 CN CH3 3-Br (Ph) 1.128 CN CH3 4-Br (Ph) 1.129 CN CH3 2-F (Ph) 1. 130 CN CH3 3-F (Ph) 1. 131 CN CH3 4-F (Ph) 1. 132 CN CH3 2-OCH3 (Ph) 1. 133 CN CH3 3-OCH3 (Ph) 1.134 CN CH3 4-OCH3 (Ph) 1.135 CN CH3 2-CH3 (Ph) 1.136 CN CH3 3-CH3(Ph) 1. 137 CN CH3 4-CH3 (Ph) 1.138 CN CH3 2-CF3 (Ph) 1. 139 CN CH3 3-CF3 (Ph) 1. 140 CN CH3 4-CF3 (Ph) 1. 141 CN CH3 2-NO2 (Ph) 1.142 CN CH3 3-NO2 (Ph) 1. 143 CN CH3 4-NO2 (Ph) 1. 144 CN CH3 2, 3-Cl (Ph) 1.145 CN CH3 2, 4-Cl (Ph) 1. 146 CN CH3 2, 5-Cl (Ph) 1.147 CN CH3 3,4-Cl (Ph) 1. 148 CN CH3 3,5-Cl (Ph) 1. 149 CN CH3 2, 3,5-Cl (Ph) 1. 150 CN CH3 2, 4,5-Cl (Ph) 1.151 CN CH3 3,4,5-Cl (Ph) 1. 152 CN CH3 2, 3-F (Ph) 1.153 CN CH3 2,4-F (Ph) 1. 154 CN CH3 2, 5-F (Ph) 1.155 CN CH3 3,4-F (Ph) 1. 156 CN CH3 3, 5-F (Ph) 1.157 CN CH3 2,3,5-F (Ph) 1. 158 CN CH3 2, 4,5-F (Ph) 1.159 CN CH3 3,4,5-F (Ph) 1.160 CF3 CH3 Ph 1. 161 CF3 CH3 2-Cl (Ph) 1.162CF3CH33-Cl (Ph) 1.163CF3CH34-Cl (Ph) 1. 164 CF3 CH3 4-F (Ph) 1. 165 CF3 CH3 4-CH3 (Ph) 1.166CH3C2H5Ph 1. 167 CH3 C2H5 2-Cl (Ph) 1.168CH3C2H53-Cl (Ph) 1.169CH3C2H54-Cl (Ph) 1.170CH3C2H54-F (Ph) 1. 171 CH3 C2H5 2-OCH3 (Ph) 1. 172 CH3 C2H5 3-OCH3 (Ph) 1. 173 CH3 C2H5 4-OCH3 (Ph) 1. 174 CH3 C2H5 4-CH3 (Ph) 1.175 CH3 C2Hs 4-NO2 (Ph) 1. 176 CH3 C2H5 2, 4-Cl (Ph) 1. 177 CH3 C2H5 2, 4-F (Ph) 1.178 CH3 n-C3H7 Ph 1.179 CH3 n-C3H7 2-Cl (Ph) 1.180 CH3 n-C3H7 3-Cl (Ph) 1.181 CH3 n-C3H7 4-Cl (Ph) 1. 182 CH3 n-C3H7 4-F (Ph) 1. 183 CH3 n-C3H7 3-OCH3 (Ph) 1. 184 CH3 n-C3H7 4-OCH3 (Ph) 1. 185 CH3 n-C3H7 4-CH3 (Ph) 1.186 CH3 n-C3H7 4-NO2 (Ph) 1.187 CH3 n-C3H7 2,4-Cl (Ph) 1.188 CH3 n-C3H7 2, 4-F (Ph) 1.189 CH3 iso-C3H7 Ph 1.190 CH3 iso-C3H7 4-Cl (Ph) 1.191 CH3 n-C4H9 Ph 1.192 CH3 n-C4H9 4-Cl (Ph) 1.193 CH3 iso-C4H9 Ph 1.194 CH3 iso-C4H9 4-Cl (Ph) 1.195 CN C2H5 Ph 1.196 CN n-C3H7 Ph 1.197 CN iso-C3H7 Ph 1.198 CN n-C4H9 Ph 1.199 CN iso-C4H9 Ph 1.200 CF3 C2H5 Ph 1.201 CF3 n-C3H7 Ph 1.202 CF3 iso-C3H7 Ph 1.203 CF3 n-C4H9 Ph 1.204 CF3 iso-C4H9 Ph 1.205 H CF3 Ph 1.206 CH3 CF3 Ph 1.207 CN CF3 Ph 1.208 CF3 CF3 Ph 1.209 H CH2=CH Ph 1.210 CH3 CH2=CH Ph 1.211 CN CH2=CH Ph 1.212 CF3 CH2=CH Ph 1.213 H CH3CH=CH Ph 1.214 CH3 CH3CH=CH Ph 1.215 CN CH3CH=CH Ph 1.216 CF3 CH3CH=CH Ph 1.217 CH3 CH3 2-Cl, 4-F (Ph) Table 2: Compounds 2.1 to 2.217 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is O ; Rl is methyl; and R2, R6, and R7 are defined as in Table 1. The following compounds are all oils and possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A: B iminoxy isomer ratio is shown: 2.11,2.12 (9: 1 A: B isomers), 2.14A (7: 3 trans: cis cyclopropane isomers), 2.17 (9: 1 A: B isomers), 2.18A, 2.20 (4: 1 A: B isomers), 2.20B, 2.34 (5: 1 A: B isomers), 2.166 (4: 1 A: B isomers), 2.170 (6: 1 A: B isomers), 2.178 (4: 1 A: B isomers), 2.189 (7: 3 A: B isomers), and 2.217 (6: 1 A: B isomers).

Table 3: Compounds 3.1 to 3.217 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is NH, R1 is methyl; and R2, R6, and R7 are defined as in Table 1. The following compouns possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A: B iminocy isomer ratio is shown: 3.11 (oil, 4: 1 A: B isomers), 3.12A (mp. 100-103 °C), 3.14A (oil, 7: 3 trans: cis cyclopropane isomers), 3.17 (oil, 9: 1 A: B isomers), 3.18A (mp. 95-99 °C), 3.20 (oil, 4: 1 A: B isomers), 3.20A (mp. 57-61 °C), 3.20B (oil), 3.34A (mp. 121-125 °C), 3.40A (oil), 3.166 (oil, 4: 1 A: B isomers), 3.170A (mp. 74-77 °C), 3.178 (oil, 4: 1 A: B isomers), 3.189 (oil, 7: 3 A: B isomers), and 3.217A (mp 110-113 °C).

Typical compounds of Formula I encompassed by the present invention wherein A, R3, R4, and R5 are hydrogen; X is CH and Z is O ; and Ri is methyl include those compounds presented in Table 4 of Formula III where R2, R6, and R7 are defined in Table 4.

Formula III Table 4 Comp R2 Rfi R7 4.1 H CH3 2-pyridyl 4.2 H CH2 3-pyridyl 4.3 H CH3 4-pyridyl 4.4 H CH2 2-pyrazinyl 4.5 H CH3 4-pyrimidinyl 4.6 H CH2 5-pyrimidinyl 4.7 H CHq 3-pyridazinyl 4.8 H CH2 4-pyridazinyl 4.9 H CH2 2-furyl 4.10 H CH2 3-furyl 4.11 H CH2 2-thienyl 4.12HCHq3-thienyl 4. 13 CH3 CH3 2-pyridyl 4. 14 CH3 CH3 3-pyridyl 4. 15 CH3 CH3 4-pyridyl 4. 16 CH3 CH3 2-pyrazinyl 4. 17 CH3 CH3 4-pyrimidinyl 4. 18 CH3 CH3 5-pyrimidinyl 4. 19 CH3 CH3 3-pyridazinyl 4. 20 CH3 CH3 4-pyridazinyl 4.21CH, CH, 2-furyl 4.22CH, CH, 3-furyl 4. 23 CH3 CH3 2-thienyl 4. 24 CH3 CH3 3-thienyl 4.25 CH3 CH3 1-CH3-3-(1H)-pyrazolyl 4.26 CH3 CH3 1-CH3-4-(1H)-pyrazolyl 4.27 CH3 CH3 5-(1H)-pyrazolyl 4.28 CH3 CH3 4-(1H)-imidazolyl 4.29 CH3 CH3 5-(1H)-imidazolyl 4.30 CH3 CH3 5-(1H)-pyrazolyl 4. 31 CH3 CH3 3-isothiazolyl 4. 32 CH3 CH3 4-isothiazolyl 4. 33 CH3 CH3 5-isothiazolyl 4. 34 CH3 CH3 4-thiazolyl 4. 35 CH3 CH3 5-thiazolyl 4. 36 CH3 CH3 3-isooxazolyl 4. 37 CH3 CH3 4-isooxazolyl 4. 38 CH3 CH3 5-isooxazolyl 4. 39 CH3 CH3 4-oxazolyl 4. 40 CH3 CH3 5-oxazolyl 4.41 CH3 CH3 1-methyl-2-(1H)-pyrrolyl 4.42 CH3 CH3 1-methyl-3-(1H)-pyrrolyl 4. 43 CH3 CH3 2-quinolinyl 4. 44 CH3 CH3 3-quinolinyl 4. 45 CH3 CH3 4-quinolinyl 4. 46 CH3 CH3 3-Cl-pyrid-2-yl 4.47 CH3 CH3 2-Cl-pyrid-3-yl 4. 48 CH3 CH3 2-Cl-pyrid-4-yl 4. 49 CH3 CH3 4-Cl-furan-2-yl 4.50 CH2 CHR 2-Cl-furan-3-yl 4.51 C2Hs CH2 2-pyridyl 4.52C2HsCH, 3-pyridyl 4.53 C2Hs CH2 4-pyridyl 4.54 C2Hs CH2 2-furyl 4.55 C2Hs CH2 3-furyl 4. 56 C2H5 CH3 2-thienyl 4. 57 C2H5 CH3 3-thienyl 4.58 n-C3H7 CH2 2-pyridyl 4.59 n-C3H7 CH2 3-pyridyl 4.60 n-C3H7 CH2 4-pyridyl 4.61 n-C3H7 CH2 2-furyl 4. 62 n-C3H7 CH3 3-furyl 4.63 n-C3H7 CH2 2-thienyl 4.64 n-C3H7 CH2 3-thienyl 4. 65 iso-C3H7 CH3 2-pyridyl 4. 66 iso-C3H7 CH3 3-pyridyl 4. 67 iso-C3H7 CH3 4-pyridyl 4. 68 iso-C3H7 CH3 2-furyl 4. 69 iso-C3H7 CH3 3-furyl 4. 70 iso-C3H7 CH3 2-thienyl 4. 71 iso-C3H7 CH3 3-thienyl 4.72n-C4H9CH, 2-pyridyl 4. 73 n-C4H9 CH3 3-pyridyl 4. 74 n-C4H9 CH3 4-pyridyl 4. 75 n-C4H9 CH3 2-furyl 4.76n-C4H9CH, 3-furyl 4. 77 n-C4H9 CH3 2-thienyl 4. 78 n-C4H9 CH3 3-thienyl 4. 79 iso-C4H9 CH3 2-pyridyl 4. 80 iso-C4H9 CH3 3-pyridyl 4. 81 iso-C4H9 CH3 4-pyridyl 4. 82 iso-C4H9 CH3 2-furyl 4. 83 iso-C4H9 CH3 3-furyl 4. 84 iso-C4H9 CH3 2-thienyl 4.85 iso-C4H9 CH3 3-thienyl 4.86 c-C3H5 CH3 2-pyridyl 4.87 c-C3H5 CH3 3-pyridyl 4.88 c-C3H5 CH3 4-pyridyl 4.89 c-C3H5 CH3 2-furyl 4.90 C-C3Hs CHs 3-furyl 4.91 c-C3H5 CH3 2-thienyl 4.92 c-C3H5 CH3 3-thienyl 4.93 CN CH3 2-pyridyl 4.94 CN CH3 3-pyridyl 4.95 CN CHs 4-pyridyl 4.96 CN CHs 2-furyl 4.97 CN CH3 3-furyl 4.98 CN CH3 2-thienyl 4.99 CN CHs 3-thienyl 4.100 CF3 CH3 2-pyridyl 4.101 CF3 CH3 3-pyridyl 4.102 CF3 CH3 4-pyridyl 4.105 CF3 CH3 2-thienyl 4.106 CF3 CH3 3-thienyl 4.107 CH3 C2H5 2-pyridyl 4.108 CH3 C2H5 3-pyridyl 4.109 CH3 C2H5 4-pyridyl 4.110 CHs C2H5 2-furyl 4.111 CH3 C2H5 3-furyl 4.112 CH3 C2H5 2-thienyl 4.113 CH3 C2H5 3-thienyl 4.114 CH3 n-C3H7 2-pyridyl 4.115 CH3 n-C3H7 3-pyridyl 4.116 CH3 n-C3H7 4-pyridyl 4.117 CH3 n-C3H7 2-furyl 4.118 CH3 n-C3H7 3-furyl 4.119 CH3 n-C4H9 2-pyridyl 4.120 CH3 n-C4H9 3-pyridyl 4.121CH3n-C4H94-pyridyl 4.122 CH3 n-C4H9 2-thienyl 4.123 CH3 n-C4H9 3-thienyl 4.124 CH3 iso-C4H9 2-pyridyl 4.125 CH3 iso-C4H9 3-pyridyl 4.126 CH3 iso-C4H9 4-pyridyl 4.127 CH3 iso-C4H9 2-thienyl 4.128 CH3 iso-C4H9 3-thienyl 4.129 CH3 cyclopropyl 2-pyridyl 4.130 CH3 cyclopropyl 3-pyridyl 4.131 CH3 cyclopropyl 4-pyridyl 4.132 CH3 cyclopropyl 2-thienyl 4.133 CH3 cyclopropyl 3-thienyl 4.134 CF3 CH3 2-pyridyl 4.135 CF3 CH3 3-pyridyl 4.136 CF3 CH3 4-pyridyl 4.134 CF3 CH3 2-furyl 4.135 CF3 CH3 3-furyl 4.136 CF3 CH3 2-thienyl 4.137 CF3 CH3 3-thienyl 4.138 CF3 C2H5 2-pyridyl 4.139 CF3 C2H5 3-pyridyl 4.140 CF3 C2H5 4-pyridyl 4.141 CF3 C2H5 2-furyl 4.142 CF3 C2H5 3-furyl 4.143 CF3 C2H5 2-thienyl 4.144 CF3 C2H5 3-thienyl 4.145 CN CH3 2-pyridyl 4.146 CN CH3 3-pyridyl 4.147 CN CH3 4-pyridyl 4.148 CN CH3 2-furyl 4.149 CN CH3 3-furyl 4.150 CN CH3 2-thienyl 4.151 CN CH3 3-thienyl 4.152 CN C2H5 2-pyridyl 4.153 CN C2H5 3-pyridyl 4.154 CN C2H5 4-pyridyl 4.155 CN C2H5 2-furyl 4.156 CN C2H5 3-furyl 4.157 CN C2H5 2-thienyl 4.158 CN C2H5 3-thienyl Table 5: Compounds 5.1 to 5.158 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is O ; R1 is methyl; and R2, R6, and R7 are defined as in Table 4.

Table 6: Compounds 6.1 to 6.158 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is NH, Rl is methyl; and R2, R6, and R7 are defined as in Table 4.

Typical compounds of Formula I encompassed by the present invention wherein A, R3, R4, and R5 are hydrogen; X is CH and Z is O ; and R1 is methyl include those compounds presented in Table 7 of Formula III where R2, R6, and R7 are defined in Table 7 Formula III Table 7 Comp R2 R6 R7 7.1 H H 2,6-Cl (Ph) 7.2 H H 2,3,6-Cl (Ph) 7.3 H H 2,4,6-Cl (Ph) 7.4 H H 2,6-Br (Ph) 7.5 H H 2,3,6-Br (Ph) 7.6 H H 2,4,6-Br (Ph) 7.7 H H 2,6-F (Ph) 7.8 H H 2,3,6-F (Ph) 7.9 H H 2,4,6-F (Ph) 7. 10 H H 2,6-CH3 (Ph) 7.11 H H 2,3,6-CH3 (Ph) 7.12 H H 2,4,6-CH3 (Ph) 7. 13 H H 2,6-CH3O (Ph) 7.14 H H 2,3,6-CH30 (Ph) 7.15 H H 2,4,6-CH30 (Ph) 7. 16 CH3 H 2, 6-Cl (Ph) 7. 17 CH3 H 2, 3,6-Cl (Ph) 7. 18 CH3 H 2, 4,6-Cl (Ph) 7.19 CHR H 2,6-Br (Ph) 7.20 CHR H 2,3,6-Br (Ph) 7.21 CHR H 2,4,6-Br (Ph) 7.22 CHR H 2,6-F (Ph) 7.23CH, H2,3,6-F (Ph) 7.24 CH3 H 2,4,6-F(Ph) 7. 25 CH3 H 2,6-CH3 (Ph) 7. 26 CH3 H 2,3,6-CH3 (Ph) 7.27CH, H2,4, 6-CH3 (Ph) 7. 28 CH3 H 2,6-CH3O (Ph) 7.29CH, H2,3,6-CH30 (Ph) 7. 30 CH3 H 2, 4,6-CH30 (Ph) 7. 31 CH3 H 2,6-NO2 (Ph) 7. 32 CH3 H 2, 6-CN (Ph) 7. 33 CH3 H 2, 3,6-CN (Ph) 7. 34 CH3 H 2, 4,6-CN (Ph) 7.35CH, H2,6-Ph (Ph) 7.36CH, H2,3,6-PhPh) 7. 37 CH3 H 2, 4,6-Ph (Ph) 7.38 CH3 H 2,6-PhO(Ph) 7.39 CH3 H 2, 3,6-PhO (Ph) 7. 40 CH3 H 2, 4,6-PhO (Ph) 7.41 CH3 H 2,6-CF3(Ph) 7. 42CH, H2, 3, 6-CF, (Ph) 7. 43 CH3 H 2, 4,6-CF, (Ph) 7.44 CH3 H 2,6-CF3O(Ph) 7.45 CH3 H 2, 3, 6-CF3O (Ph) 7. 46 CH3 H 2, 4,6-CFO (Ph) 7.47CH, H2,3,4, 6-Cl (Ph) 7. 48CH, H2, 3, 5, 6-Cl (Ph) 7. 49 CH3 H 2, 3,4,5,6-Cl (Ph) 7. 50 CH3 H 2, 3,4,6-Ph (Ph) 7. 51 CH3 H 2, 3, 5,6- Ph (Ph) H 2,3,4,5,6- Ph (Ph) 7. 53 CH3 H 2, 3,4,6-PhO (Ph) 7. 54 CH3 H 2, 3,5, 6- PhO(Ph) 7. 55 CH H 2, 3,4,5, 6-PhO(Ph) 7.56 CH3 H 2, 3,4,6-Br (Ph) 7. 57 CH3 H 2,3,5, 6-Br (Ph) 7. 58 CH3 H 2,3,4,5,6-Br (Ph) 7. 59 CH3 H 2,3,4,6-F(Ph) 7. 60 CH3 H 2,3,5, 6-F (Ph) 7. 61 CH3 H 2, 3,4,5, 6-F (Ph) 7. 62 CH3 H 2, 3,4, 6-CH3 (Ph) 7.63 CH3 H 2, 7. 64 CH3 H 2, 3,4,5, 6-CHR (Ph) CH3 H 2, 3,4, 6-C2H5 (Ph) 7. 66 CH3 H 2, 3,5, 6- C2H5(Ph) 7. 67 CH3 H 2,3,4, 5,6- C2Hs (Ph) 7. 68 CH3 H 2, 3,4, 67-CH3O(Ph) CH3 H 2, 3,5,6-CHO (Ph) 7. 70 CH H 2, 3,4,5, 6-CH3O (Ph) 7. 71 CH3 H 2, 3,4, 6-CF3 (Ph) 7. 72 CH3 H 2, 3,5, 6-CF3 (Ph) 7. 73CH, H2, 3,4,5, 6-CF3 (Ph) 7. 2, 3,4, 6-CF3O(Ph) 7. 2, 3,5, 6-CF3O(Ph) 7. 76 CH3 H 2, 3,4,5, 6-CF3O(Ph) 7. 77 CH3 H 2, 3,4,6-CN (Ph) 7. 78 CH3 H 2, 3,5,6-CN (Ph)<BR> <BR> <BR> <BR> <BR> 7.79 CH3 H 2,3,4,5,6-CN (Ph) 7.80CH3 H 2-Br-6-Cl(Ph) 7.81 CH3 H 2-Br-6-F(Ph) 7.82-Br-6-CHq (Ph) <BR> <BR> 7.83 CH3 H 2-Br-6-CF3(Ph)<BR> <BR> <BR> <BR> 7.84CH3 H 2-Br-6-CH3O(Ph) 7.85CH3 H 2-Br-6-CF3O(Ph) 2-Br-6-CN (Ph) 7.87 CH3 H 2-Cl-6-F(Ph) 7.88CH3 H 2-Cl-6-CH3 (Ph) 7.89 CH3 H 2-Cl-6-CF3 (Ph)<BR> <BR> <BR> <BR> 7.90Ch3 H 2-Cl-6-CH3O(Ph)<BR> <BR> <BR> <BR> 7. 91 CHq H 2-Cl-6-CFRO (Ph) 7.92 CH3 H 2-Cl-6-CN (Ph) 7.93 CH3 7.94CH3 H 2-F-6-CF3(Ph) 7. 95 CHq H 2-F-6-CHROh) 2-F-CF3O(Ph) 7.97CH3 H 6-CN-2F (Ph) 7 98 CHq H 2-CHR-6-CFR (Ph) H 6-CH3O-2-CH3(Ph) 7.100CH3 H 2-CH3-6-CF3O(Ph) 7.101 CH3 H 6-CN-2-OCH3 (Ph) 7.102CH, H6-CN-2-CH, (Ph) 7. 103 CHq H 3, 6-Cl-2-F (Ph) 7.104 CH3 H 3Cl-2,6-F(Ph) 7.105CH3 H 4-Cl-2,6-F(Ph) 7.106CH3 H 2-Br-3,6-Cl (Ph) 7. 2,3-Br-6-Cl (Ph) CH3 H 3-Cl-2, 6Br (Ph) 7.109 CH3 H 2,6-Cl-3-F (Ph) 7.110 CH3 H 2,3-Cl-6-F (Ph) 7. 111 CH H 2-Cl-3, 6-F (Ph) 7.112 CH3 H 3-Br-2,6-Cl (Ph) 7.113 CH H 3-Br-2,6-F (Ph) 7.114 CH3 H 3-Br-6Cl-2-F (Ph) 7.115 CH3 H 2-Br-5Cl-6-F (Ph) 7.116 CHq H 2, 6-Br-3-F (Ph) 7.117 CH3 H 2, 5-Br-6-F (Ph) 7.118 CH3 H 2,4-Cl-6F (Ph) 7.119 CH3 H 2,6-Cl-4F (Ph) 7.120 CH3 H 2,4-Cl-6Br (Ph) 7.121 CH3 H 2,6-Cl-4Br(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.122CH, H2,4-F-6-Cl (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.123CH, H2, 4-F-6-Br (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.124CH, H2,6-F-4-Br (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.125 CH3 H 2,4-Br-6-F(Ph)<BR> 7.126 CHq H 2,4-Br-6-Cl (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.127 CH3 H 2,6-Br-4-Cl (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.128 CHq H 2,6-Br-4-F (Ph)<BR> <BR> <BR> <BR> <BR> 7.129 CH3 H 2,4-Cl-6-CH3 (Ph)<BR> 7.130 CH3 H 2,6-Cl-4-CH3(Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.131 CH3 H 2-Cl-4,6-(CH3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.132 CHq H 4-Cl-2,6-(CHR) (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.133 CH3 H 2,4-F-6-CH3 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.134 CHq H 2, 6-F-4-CHR (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.135 CH3 H 2-F-4,6-(CH3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.136 CH3 H 4-F-2,6-(CH3)2 (Ph)<BR> 7.137 CHq H 2, 4-Br-6-CHR (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.138 CHq H 2, 6-Br-4-CHR (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.139 CH3 H 2-Br-4,6-(CH3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.140 CH3 H 4-Br-2,6-(CH3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.141 CHq H 2, 4-Cl-6-CFR (Ph)<BR> 7.142 CHq H 2, 6-Cl-4-CFR (Ph)<BR> <BR> <BR> <BR> <BR> 7.143 CH3 H 2-Cl-4,6-(CF3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.144 CH3 H 4-Cl-2,6-(CF3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.145 CH3 H 2,4-F-6-CF3 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.146 CH3 H 2,6-F-4-CF3 (Ph)<BR> 7.147 CH3 H 2-F-3,6-(CF3)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.148 Ch3 H 3-F-2,6-(CF3)2 (Ph)<BR> <BR> <BR> <BR> 7.149 Ch3 H 2,3-Br-6-CF3 (Ph)<BR> <BR> <BR> 7.150 CH3 H 2,6-Br-3-CF3 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.137 CH3 H 2-Br-4,6-(CF3)2 (Ph)<BR> <BR> 7.138CH3 H 4-Br-2,6-(CF3)2(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.139 Ch3 H 2,4-Cl-6-CF3O(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.140 CH3 H 2,6-Cl-4-CF3O(Ph)<BR> <BR> <BR> 7.141 CH3 H 2-Cl-4,6-(CF3O)2(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.142 CH3 H 4-Cl-2,6-(CF3O)2(Ph)<BR> <BR> <BR> <BR> <BR> 7.143 CH3 H 2,4-F-6-CF3O(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.144CH3 H 2,6-F-4-CF3O(Ph) 7.145 CH3 H 2-F-4,6-(CF3O)2 (Ph) 7.146 CH3 H 4-F-2,6-(CF3O)2 (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.147 CH3 H 2,4-F-6-CF3O(Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7.148 CH3 H 2,6-F-4-CF3O(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7.149 CH3 H 2-F-4,6-(CF3O)2(Ph)<BR> <BR> <BR> 7.150CH3 H 4-F-2,6-(CF3O)2(Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7. 151 CH H 2-Br-3, 4,6-Cl (Ph)<BR> <BR> <BR> <BR> <BR> <BR> 7. 152 CH H 6-F-2,4,5-Cl (Ph)<BR> <BR> <BR> <BR> <BR> 7. 153 Ch3 H 6-Cl-2, 4,5-Br (Ph)<BR> 7. 154 Ch3 H 6-F-2, 4,5-Br (Ph)<BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> <BR> 7. 155 CH H 2-Br-3, 4,6-F (Ph) 7.156 CH3 H 2-Cl-3, 4,6-F (Ph) 7. 157 CH3 H 6-CH3-2, 4,5-Cl (Ph) 7. 158 CH3 H 6-CH3-2, 4,5-Br (Ph) 7.159 CHq H 6-CHR-2,4,5-F (Ph) 7.160 H6-CF,-2, 4,5-Cl (Ph) 7.161CH, H6-CF,-2,4,5-Br (Ph) 7.162 Ch3 H 6-CF3-2,4,5-F(Ph) 7.163 CHq H 6-CFRO-2,4,5-Cl (Ph) 7.164 CHq H 6-CFRO-2,4,5-Br (Ph) 7. 165 CH3 H 6-CF3O-2, 4,5-F (Ph) 7.166CH, H2-Br-3,5,6-Cl (Ph) 7.167 CHq H 2-Br-3,5,6-F (Ph) 7.168 CHq H 2-Cl-3,5,6-F (Ph) 7.169 CHq H 6-F-2,3,5-Cl (Ph) 7.170CH, H6-Cl-2,3,5-Br (Ph) 7. 171 CH3 H 6-F-2, 3,5-Br (Ph) 7.172 H6-CH,-2, 3,5-Cl (Ph) 7. 173 CH3 H 6-CH3-2, 3,5-Br (Ph) 7. 174 Ch3 H 2-CH3-3, 5,6-F (Ph) 7. 175 CH3 H 6-CF3-2, 3,5-Cl (Ph) 7.176CH, H6-CF,-2,3,5-Br (Ph) 7. 177 Ch3 H 2-CF3-3, 5,6-F (Ph) 7. 178 CH3 H 6-CF3O-2, 3,5-Cl (Ph) 7.179 CHq H 6-CFRO-2,3,5-Br (Ph) 7. 180 CH3 H 2-CF3O-3,5,6-F(Ph) 7.172 CHq H 4-Br-2,3,5,6-Cl (Ph) 7. 173 CH3 H 4-F-2, 3,5,6-Cl (Ph) 7. 174 Ch3 H 4-Cl-2, 3,5,6-Br (Ph) 7. 175 CH3 H 4-F-2, 3,5,6-Br (Ph) 7.176 CH9 H 4-Cl-2,3,5,6-FPh) 7. 177 CH3 H 4-Br-2, 3,5,6-F (Ph) 7. 178 Ch3 H 2-Br-3, 4,5,6-Cl (Ph) 7. 179 Ch3 H 2-F-3, 4,5,6-Cl (Ph) 7.180 CHq H 2-Cl-3,4,5,6-F (Ph) 7.181 CHR H 2-Br-3,4,5,6-F (Ph) 7.182 CHq H 6-Cl-2,3,4,5-Br (Ph) 7. 183 CH3 H 6-F-2, 3,4,5-Br (Ph) 7. 184 CH3 H 4-Ch3-2, 3,5,6-Cl (Ph) 7. 185 CH3 H 4-CH3-2, 3,5,6-Br (Ph) 7.186 CHq H 4-CHR-2,3,5,6-F (Ph) 7. 187 CH3 H 4-CF3-2, 3,5,6-Cl (Ph) 7. 188 Ch3 H 4-CF3-2, 3,5,6-Br (Ph) 7.189 CH3 H 4-CF3-2, 3,5,6-F (Ph) 7. 190 Ch3 H 4-CH3O-2, 3,5,6-Cl (Ph) 7. 191 CH3 H 4-CF3O-2, 3,5,6-Br (Ph) 7. 192 Ch3 H 4-CF3O-2, 3,5,6-F (Ph) 7. 193 Ch3 H 4-CF3O-2, 3,5,6-Cl (Ph) 7. 14 CH3 H 6-CH3-2, 3,4,5-Cl (Ph) 7. 195 CH3 H 6-CH3-2, 3,4,5-BrPh) 7.196 CHR H 2-CH3-3, 4,5,6-F (Ph) 7. 197 CH3 H 6-CFRO-2, 3,4,5-Cl (Ph) 7. 198 CH3 H 6-CFRO-2, 3,4,5-BrPh) 7.199 CHR H 2-CF,O-3, 4,5,6-F (Ph) 7. 200 CH3 CH3 2,6-Cl (Ph) 7. 201 Ch3 CH3 2,3,6-Cl (Ph) 7. 202 CH3 CH3 2,4,6-Cl (Ph) 7. 203 CH3 CH3 2,6-Br (Ph) 7. 204 CH3 CH3 2,3,6-Br (Ph) 7. 205 CH3 CH3 2,4,6-Br (Ph) 7. 206 CH3 CH3 2,6-F (Ph) 7. 207 CH3 CH3 2, 3,6-F (Ph) 7. 208 CH3 CH3 2,4,6-F (Ph) 7. 209 CH3 Ch3 2,6-CH3 (Ph) 7. 210 CH3 CH3 2,3,6-CH3 (Ph) 7.211 CHR C2Hs 2,4, 6-CH3 (Ph) 7. 212 CH3 n-C3H7 2, 6-Cl (Ph) 7. 213 CH3 iso-C3H7 2,3,6-Cl (Ph) 7.214 CHR n-C4Hs 2,4,6-Cl (Ph) 7.215 CHR iso-C4Hs 2,6-Cl (Ph) 7. 216 CH3 Ch2=CH 2,3,6-Cl (Ph) 7. 217 CH3 CH3CH=CH 2,4,6-Cl (Ph) 7. 218 CN H 2,6-Cl (Ph) 7. 219 CN CH3 2,3,6-Cl (Ph) 7. 220 CN C2H5 2,4,6-Cl (Ph) 7.221 CN n-C3H7 2,6-Cl (Ph) 7.222 CN iso-CsH7 2,3,6-Cl (Ph) 7. 223 CN n-C4H9 2,4,6-Cl (Ph) 7.224CN iso-C4H9 2,6-Cl (Ph) 7.225 CN CH2=CH 2,3,6-Cl (Ph) 7.226 CN CH3CH=CH 2,4,6-Cl (Ph) 7.227 CFR H 2,6-Cl (Ph) 7. 228 CF3 CH3 2,3,6-Cl (Ph) 7. 229 CF3 C2H5 2,4,6-Cl (Ph) 7.230 CFR n-C3H7 2, 6-Clh) 7. 231 CF3 iso-C3H7 2,3,6-Cl (Ph) Table 8 : Compounds 8.1 to 8.231 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is O ; R1 is methyl; and R2, R6, and R7 are defined as in Table 7. The following compounds possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A: B iminoxy isomer ratio is shown: 8.16 (oil, 9: 1 A: B isomers), 8. 16A (oil), 8.16B (oil), 8.22 (oil, 7.9: 2.1 A: B isomers), and 8.200 (oil, 4: 1 A: B isomers).

Table 9: Compounds 9.1 to 9.231 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is NH, R1 is methyl ; and R2, R6, and R7 are defined as in Table 7. The following compounds possess either a trans cyclopropane or an enriched trans cyclopropane stereochemistry for R7 and the iminoxy substituent, and the indicated A: B iminoxy isomer ratio is shown: 9.16 (oil, 9: 1 A: B isomers), 9.16A (oil), 9.16B (mp. 140-146 °C), 9.22A (oil) and 9.22B (oil), and 9.200 (oil, 9: 1 A: B isomers).

Typical compounds of Formula I encompassed by the present invention wherein A, R3, R4, and R5 are hydrogen; X is CH and Z is O ; and Ri is methyl include those compounds presented in Table 10 of Formula III where R2, R6, and R7 are defined in Table 10.

Formula III Table 10 Comp R2 R6 R7 10.1 H H 2, 4-Cl-pyrid-3-yl 10.2 H H 2,4-F-pyrid-3-yl 10.3 H H 2-Cl-4-F-pyrid-3-yl 10.4HH2, 4- (CH,),-pyrid-3-yl 10.5 H H 3, 5-Cl-pyrid-4-yl 10.6 H H 3,5-F-pyrid-4-yl 10.7 H H 3-Cl-5-F-pyrid-4-yl 10.8 H H 3, 5-(CHq) 2-pyrid-4-yl 10.9 H H 4,6-Cl-pyrimidin-5-yl 10.10 H H 4,6-F-pyrimidin-5-yl 10.11 H H 4, 6-(CHq)-pyrimidin-5-yl 10.12 H H 4-Cl-6-F-pyrimidin-5-yl 10. 13 Ch3 H 2, 4-Cl-pyrid-3-yl 10. 14 Ch3 H 2, 4-F-pyrid-3-yl 10.15 CH3 H 2-Cl-4-F-pyrid-3-yl 10.16 CHq H 2, 4-(CHg-pyrid-3-yl 10.17 CHq H 3,5-Cl-pyrid-4-yl 10.18 CHq H 3,5-F-pyrid-4-yl 10.19 CHq H 3-Cl-5-F-pyrid-4-yl 10.20 CH3 H 3,5-(CH3)2-pyrid-4-yl 10.21CH, H4, 6-Cl-pyrimidin-5-yl 10.22 CHq H 4,6-F-pyrimidin-5-yl 10.23 CH3 H 4,6-(CH3)2-pyrimidin-5-yl 10.24 CH3 H 4-Cl-6-F-pyrimidin-5-yl 10.25CH, H3,5-Cl-pyridazin-4-yl 10.26 CHq H 3, 5-F-pyridazin-4-yl 10. 27 CH3 H 3, 5-Br-pyridazin-4-yl 10.28 CH3 H 3,5-(CH3)2-pyridazin-4-yl 10.29 CHq H 3-Cl-5-F-pyridazin-4-yl 10.30 CHq H 5-Cl-3-F-pyridazin-4-yl 10.31 CHq H 3-Br-5-Cl-pyridazin-4-yl 10.32 CHq H 5-Br-3-Cl-pyridazin-4-yl 10. 33 CH3 H 2, 4-Cl-thien-3-yl 10. 34 Ch3 H 2, 4-F-thien-3-yl 10.35 CH3 Ch3 2-Cl-4-F-thien-3-yl 10. 36 CH3 CH3 2-F-4-Cl-thien-3-yl 10. 37 CH3 CH3 2,4-(CHq)-thien-3-yl 10. 38 CH3 CH3 2, 4,5-Cl-thien-3-yl 10. 39 CH3 CH3 2,4,5-F-thien-3-yl 10.40 CH3 CH3 2,4,5-CH3-thien-3-yl 10. 41 CH3 Ch3 2,4-Cl-furan-3-yl 10. 42 CH3 CH3 2,4-F-furan-3-yl 10. 43 CH3 CH3 2-Cl-4F-furan-3-yl 10.44 CH3 CH3 2-F-4Cl-furan 3-yl 10. 45 CH3 CH3 2, 4-(CH3)2-furan-3-yl 10. 46 Ch3 Ch3 2,4,5-Cl-furan-3-yl 10. 47 CH3 CH3 2,4,5-F-furan-3-yl 10. 48 CH3 Ch3 2,4,5-CH,-furan-3-yl 10. 49 Ch3 CH3 2,4-Cl-1-CHq-1H-pyrrol-3-yl 10.50 CHq CHR 2,4-F-1-CHq-1H-pyrrol-3-yl 10.51 CH3 CH3 2-Cl-4F-1-CH3-1H-pyrrol-3-yl 10.52 CH3 CH3 2-F-4Cl-1-CH3-1H-pyrrol-3-yl 10.53 CHI CH., 3,5-Cl-isoxazol-4-yl 10. 54 CH3 CH3 3,5-F-isoxazol-4-yl 10.55 CH3 CH3 3,5-Br-isoxazol-4-yl 10. 56 Ch3 CH3 3,5-CH,-isoxazol-4-yl 10.57 CH3 CH3 3,5-CH3O-isoxazol-4-yl 10. 58 CH3 CH3 3,5-CFO-isoxazol-4-yl 10. 50 CH3 CH3 3,5-Cl-isothiazol-4-yl 10.60CH, CH, 3,5-F-isothiazol-4-yl 10. 61 CH3 CH3 3,5-Br-isothiazol-4-yl 10. 62 CH3 CH3 3,5-CH,-isothiazol-4-yl 10.63 CH3 CH3 3,5-CH3O-isothiazol-4-yl 10. 64 CH3 CH3 3, 5-CF3O-isothiazol-4-yl 10. 66 CH3 CH3 3,5-Cl-1-CHq-1H-pyrazol-4-yl 10.67 CH3 CH3 3,5-F-1-CH3-1H-pyrazol-4-yl 10. 68 CH3 CH3 3,5-Br-l-CH,-lH-pyrazol-4-yl 10.69 CH3 CH3 3-Cl-5F-1-CH3-1H-pyrazl-4-yl 10. 70 CH3 CH3 2,4-Cl-pyrid-3-yl 10.71 CH3 C2H5 2, 4-F-pyrid-3-yl 10.72 CH n-C3H7 2-Cl-4-F-pyrid-3-yl 10. 73 CH3 iso-C3H7 2,4-(CH3)2-pyrid-3-yl 10. 74 CH3 n-C4H9 3, 5-Cl-pyrid-4-yl 10.75 CHq iso-C4Hs 3,5-F-pyrid-4-yl 10.76 CHq CH2=CH 3-Cl-5-F-pyrid-4-yl 10.77 CN CH3CH=CH 2,4-Cl-pyrid-3-yl 10.78 CN CHq 2,4-F-pyrid-3-yl 10.79 CN CH3 2-Cl-4-F-pyrid-3-yl 10.80 CN CHq 2, 4-(CH3)2-pyrid-3-yl 10.81 CN CHq 3,5-Cl-pyrid-4-yl 10.82CNCH, 3,5-F-pyrid-4-yl 10.83 CN CHq 3-Cl-5-F-pyrid-4-yl 10.84 CN CHI 4,6-Cl-pyrimidin-5-yl 10.85 CN CHI 4,6-F-pyrimidin-5-yl 10.86CNCH, 2,4-Cl-thien-3-yl 10.87 CN CHI 2,4-F-thien-3-yl 10.88 CN CHI 2-Cl-4-F-thien-3-yl 10.89 CN CHq 2-F-4-Cl-thien-3-yl 10.90 CN Ch3 2,4-(CH3)2-thien-3-yl 10.89 CN CHq 2,4,5-Cl-thien-3-yl 10. 90 CN CH3 2, 4,5-F-thien-3-yl 10.91 CN CHq 2,4,5-CH.,-thien-3-yl 10. 92 CN C2H5 2, 4-Cl-pyrid-3-yl 10.93 CN n-C3H7 2,4-Cl-pyrid-3-yl 10.94 CN iso-CsH7 2, 4-Cl-thien-3-yl 10.95 CN n-C4Hs 2,4-F-thien-3-yl 10.96CNiso-C4H92-Cl-4-F-thien-3-yl 10.97 CN CH2=CH 2-F-4-Cl-thien-3-yl 10. 98 CN CH3CH=CH 2,4-(CH3)2-thien-3-yl 10. 99 CF3 CH3 2,4-Cl-pyrid-3-yl 10. 100 CF3 Ch3 2, 4-F-pyrid-3-yl 10. 101 CF3 CH3 2,4-Cl-thien-3-yl 10.102CF, CH, 2,4-F-thien-3-yl 10.103CF, CH, 2-Cl-4-F-thien-3-yl 10. 104 CF3 CH3 2-F-4-Cl-thien-3-yl 10.105 CF3 CH3 2, 4-(CH3)2-thien-3-yl 10. 106 CF3 CH3 3,5-Cl-isothiazol-4-yl 10.107 CF3 CH3 3,5-F-isothiazol-4-yl 10-108 CF., n-C3H7 2, 4-Cl-pyrid-3-yl 10. 109 CF3 iso-C3H7 2, 4-F-pyrid-3-yl 10. 110 CF3 n-C4H9 3, 5-Cl-pyrid-4-yl 10. 111 CF3 iso-C4H9 3, 5-F-pyrid-4-yl 10. 112 CF3 CH2=CH 2, 4-Cl-pyrid-3-yl 10.113 CF3 CH3CH=CH 2, 4-F-pyrid-3-yl Table 11: Compounds 11.1 to 11.113 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is O ; R1 is methyl; and R2, R6, and R7 are defined as in Table 7.

Table 12: Compounds 12.1 to 12.113 are compounds of Formula I wherein A, R3, R4, and R5 are hydrogen; X is N and Z is NH, R1 is methyl; and R2, R6, and R7 are defined as in Table 7.

Compounds of the present invention are prepared according to the following synthetic schemes. Scheme A describes the preparation of compounds of the Formula (I) where A and R2 to R7 are as defined in Tables 1-2,4-5,7-8, and 10-11; X is CH or N, and Z is O (compounds of Formula VI and VII). The cyclopropyl oximes (V) are reacted with the appropriately substituted benzyl derivatives (IV), where Z is a halogen, such as bromo, chloro or iodo, preferably a benzyl bromide. A cyclopropyl substituted oxime represented by the general formula (V) is treated, at room temperature, with an appropriate base to form an anion, followed by the addition of the benzyl bromide (IV). Typical bases employed are metal hydrides such as sodium hydride, alkoxides such as sodium methoxide and hydroxide bases such as sodium or potassium hydroxide and alkali bases such as sodium or potassium carbonate. Typical solvents employed with hydride bases are N, N-dimethylformamide (DMF) and tetrahydrofuran (THF); with hydroxide bases DMF, THF, methyl ethyl ketone (MEK) and acetone and with alkali bases solvents such as DMF, acetone, and MEK.

As shown in Scheme A, the N-0 bond in C (R2) =N-O-, appears in the E position (assuming is the larger substituent), It should be recognized that the Z isomer can also be produced as well as mixtures. When isomers are produced they are designated isomer A (higher Rf on thin layer chromatography) and isomer B (lower Rf on thin layer chromatography). The determination of which isomer, A or B possesses the E or Z geometry can be made by such conventional techniques as X ray crystallography or by spectroscopic means such as nuclear magnetic resonance spectroscopy. For the compounds of the present invention isomer A has been assigned the E iminoxy configuration and isomer B, the Z iminoxy configuration.

Scheme A Compounds of formula VI (X is CH) are prepared by alkylation with methyl E-a- (2-bromomethylphenyl)-p-methoxyacrylate in the presence of a base, preferably NaOH or KOH, in a solvent, preferably acetone or methyl ethyl ketone. Methyl E-oc-(2-bromomethylphenyp-ß-methoxyacrylate, as a single E isomer, can be prepared in two steps from 2-methylphenylacetate as described previously in US Patent Number 4,914,128, columns 3-4. Compounds of formula VII (X=N) are prepared by the reaction with methyl E-2- (bromomethyl) phenylglyoxylate O-methyloxime in the presence of a base, preferably NaOH or KOH, in a solvent, preferably acetone or methyl ethyl ketone. Methyl 2- (bromomethyl) phenylglyoxylate O-methyloxime can be prepared as described in US Patent Numbers 4,999,042, columns 17-18 and 5,157,144, columns 17-18. Methyl 2- (bromomethyl) phenylglyoxylate 0-methyl- oxime is prepared from methyl 2-methylphenyl-acetate by treatment with an alkyl nitrite under basic conditions to provide after methylation, methyl 2- methyl-phenyl-glyoxalate 0-methyl oxime which can also be prepared from methyl 2-methyl-phenylglyoxalate by treatment with 2-hydroxylamine hydrochloride and methylation or by treatment with methoxylamine hydrochloride.

Scheme B As shown in scheme B compounds of formula IX (X is N) and of Tables 3, 6,9, and 12 can be prepared by the aminolysis of oximinoacetate (VII). The aminolysis of oximinoacetate to oximinoacetamides has been described in US Patent Numbers 5,185,342, cols. 22,48 and 57,5,221,691, cols. 26-27 and 5,407,902, col. 8. For example, compounds of formula VII and of Table 2 are treated with 40% aqueous methylamine in methanol to provide compounds of formula IX and of Table 3 of formula I where Z is NH. Alternatively, as is shown in scheme B intermediate unsaturated oximes (V) are reacted with N- methyl (E)-2-methoxyimino-2- [2- (bromomethyl) phenyl] acetamide VIII in the presence of a base such as an hydroxide base preferably in a solvent such as acetone or methyl ethyl ketone to provide compounds of formula (IX). N-methyl (E)-2-methoxy-imino-2- [2- (bromomethyl) phenyl] acetamide is described in US Patent Number 5,387,714, col. 13.

The oximes of the general formula (V) can be obtained, as shown in Scheme C, by reacting the corresponding cyclopropyl aldehyde or ketone (X) with hydroxylamine hydrochloride from room temperature to reflux, preferably at room temperature, in an appropriate solvent such as methanol or ethanol in the presence of an appropriate alkali such as sodium hydroxide, potassium carbonate or pyridine. A general description of the synthesis of oximes with hydroxylamine is described in March, Advanced Organic Chemistry, 4th Ed, pp.

906-907 and references therein. The oximes of the general formula (III) when obtained as a mixture of syn or anti oxime isomers can be separated into individual isomers and alkylated as described in scheme A and B. When a mixture of oximes of the general formula (III) are used in Schemes A and B the compounds of the formula VI, VII and IX can be separated into their individual isomers by conventional chromatographic techniques.

Scheme C The cyclopropyl aldehydes or ketones (X) are prepared by conventional techniques. The unsaturated intermediate XI (Scheme D) is reacted with a sulfur ylide, prepared from a dimethylsulfoxonium salt in the presence of a base, resulting in the substituted acyl cyclopropanes, X, as shown in Scheme D. The chemistry of sulfur ylides is described in Trost and Melvin, Sulfur Ylids, Academic Press, New York, NY 1975 and in Block, Reactions of Organosulfur Compounds, pp. 91-123, Academic Press, New York, NY 1978. Typical reaction conditions for sulfur ylide formation from a dimethylsulfoxonium salt utilizes bases such as hydroxides, metal hydrides and alkoxides in solvents such as dimethoxyethane, dimethylsulfoxide and water depending on the base employed.

The reactions are conducted from 0 to 20°C preferably from 10-15°C and preferably with alkali metal hydroxides in dimethylsulfoxide. Typically dimethylsulfoxonium methylide is prepared from trimethylsulfoxonium iodide in dimethylsulfoxide in the presence of powdered sodium hydroxide at room temperature. The unsaturated aldehydes or ketones (XI) are added dropwise to the ylide and stirred at room temperature.

Scheme D XI X The a, (3-unsaturated aldehydes or ketones XI can be prepared by conventional condensation techniques. A extensive description of the synthesis of a, ß-unsaturated aldehydes or ketones (enones) is described in March, Advanced Organic Chemistry, 4th Ed, pp. 937-955 and references therein. For example Organic Reactions, Volume 16 describes the general aldol condensation of ketones and aldehydes. For intermediates of formula XI of this invention, in general the ketones and aldehydes are R7COR6 (XII) and R2COCH2R3 (XIII) where R2, R3, R6, and R7 are defined previously. When R6 is hydrogen, the aldehydes R7CHO (XIV), are for example benzaldehydes (arylCHO) or heterocyclic aldehydes substituted with from 2 to 5 substituents wherein the positions on the aryl and heterocyclic ring adjacent to the bond to the cyclopropyl ring, in Formula I, are both substituted. These substituted benzaldehyes or heterocyclic aldehydes are commerically available or prepared by conventional techniques. The aldehydes R7CHO (XIV) are reacted with the ketones R2COCH2R3, XIII, (as shown in Scheme E) to provide the intermediates enones XV. Typically the ketone, R2COCH2R3, is dissolved in a hydroxylic solvent, such as methanol or ethanol, to which is added dropwise the aldehyde R7CHO followed by the base or alternatively a solution of the aldehyde in an aqueous basic solution is added. The typical bases used can be alkali metal hydroxides, such as barium, potassium or sodium hydroxide and the dropwise addition is conducted from 0°C to 35°C preferably at ambient temperature. When the enone is derived from acetone (R2 is methyl and R3 is hydrogen) the solvent can be acetone to which is added R7COR6 followed by the aqueous hydroxide solution. Preferably the aldehyde is dissolved in a solvent mixture of acetone: water (1: 5) to which is added the base while stirring at room temperature.

Scheme E When R6 is not hydrogen, R7COR6 (XII) are the ketones arylCOR6 or heterocyclic ketones, substituted with from 2 to 5 substituents wherein the positions on the aryl and heterocyclic rings adjacent to the bond to the cyclopropyl ring, in Formula I, are both substituted or aryl or heterocyclic ring is unsubstituted or substituted from 1 to 4 substituents wherein at least one of the positions on the aryl or heterocyclic rings adjacent to the bond to the cyclopropyl ring, in Formula I, is a hydrogen. For the compounds of formula I where R6 is not hydrogen the intermediate unsaturated aldehydes and ketones XI are prepared, as shown in Scheme F, according to the procedures described in US Patent Number 3,950,427, col. 17 line 20, to provide after purification the E diastereiosmer (R7 is trans to R2CO in XI). In a typical preparation a ketone such as R7COR6 is reacted with an ethyl trans 3-ethoxycrotonate in dimethylformamide in the presence of potassium t-butoxide followed by acidic hydrolysis and decarboxylation to give XI. The crotonates, XVI, can be prepared from substituted ethyl acetoketones by conventional techniques Scheme F Alternatively the a, (3-unsaturated cyclopropyl ketones X can be prepared from cyclopropyl nitriles XIV which are prepared via cyclopropanation of the acrylonitriles XVIII as is described in Scheme G. The acrylonitriles XVIII starting materials, shown in Scheme G can be prepared by conventional synthetic methods as described in March, Advanced Organic Chemistry, 4th Ed, pp. 937-955 and references therein. For example the nitrile derivative R3CH2CN is condensed with the ketone or aldehyde R7COR6 in the presence of a base to provide the acrylonitriles XIII. Typically the a nitrile is dissolved in a solvent such as ethanol and water to which is added the aldehyde or ketone followed by a base. Typical bases used can be alkali metal hydroxides, such as barium, potassium or sodium hydroxide and the mixture is stirred typically at ambient temperature.

The acrylonitrile XVIII is treated as is described in Scheme D with a sulfur ylide to provide the cyclopropyl nitriles XVII. The cyclopropyl nitrile XVII is transformed to the cyclopropyl ketone by organometallic addition to the nitrile followed by hydrolysis. For example the standard Grignard reagents R2MgX or organolithium reagents, R2Li, add to the nitrile functionality to provide the ketone X. The addition reaction to nitriles is described in March, Advanced Organic Chemistry, 4th Ed, pp. 935-936 and references cited therein.

The cyclopropyl nitrile XVII can be transformed to the cyclopropyl aldehyde X' (where R2 is H) by standard reductive methods such as with diisobutylaluminum hydride (DiBAL). The formation of aldehydes from the reduction of nitriles is described in March, Advanced Organic Chemistry, 4th Ed, pp. 919-920 and references cited therein.

Scheme G A direct synthesis of compounds of the formula VII or IX is shown in Scheme H. Compounds of the Formula VII or IX can be prepared directly from the functionalized cyclopropyl ketones or aldehydes, X, by condensation with the aminoxy intermediate XIX. The preparation of aminoxy intermediate XIX is described in US Patent Number 5,194,662. The aminoxy intermediate XIX is prepared in a two step sequence by the alkylation of IV (where X is N) with N- hydroxyphthalimide which is treated with hydrazine to provide XIX. The aminoxy intermediate XIX is condensed with ketones or aldehydes X to provide VII which are treated as shown in scheme B to provide IX.

Scheme H The compounds of this invention can be made according to the following procedures: Example 1 Preparation of E and Z imine isomers : (E, E) and Z, E) Methyl 2-f2- ((trans-1-(2-(2', 6'-dichlorophenyl) cvelopropyl) ethylidene)- aminooxymethyl) phenyl]-2-methoxyiminoacetate Compound 8.16.

8.16A and 8.16B of Table 8 Preparation of 4-(2 6-dichlorophenyl)-3-buten-2-one To a 1000 ml round bottom flask equipped with mechanical stirrer, and nitrogen inlet were charged 26.5 g (0.15 moles) of 2, 6-dichlorobenzaldehyde, 125 mls of acetone, 600 mls of water, and 9.3 g (0.23 moles) of sodium hydroxide. The mixture was stirred for 12 hours at room temperature. Analysis of an aliquot by GC indicated complete reaction. The resulting solid was collected by vacuum filtration, and washed with 100 mls of water, 100 mls of hexane, and dried in vacuuo at 40°C for 3 hours. 31.4 g of the title compound, 4- (2, 6-dichlorophenyl)-3- buten-2-one, was isolated as a pale yellow solid in 98% isolated yield.

NMR 300 MHz 1H CDCl3 2.43 (s, 3H); 6.80 (d, 1H); 7.18-7.38 (m, 1H) ; 7.4 (d, 2H); 7.6 (d, 1H).

Preparation of trans-1- (2, 6 dichlorophenyl)-2-acetyl-cyclopropane To a 1000 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged 33.2 g (0.151 moles) of trimethyl sulfoxonium iodide, 6.1 g (0.151 moles) of powdered sodium hydroxide, and 300 mls DMSO. The mixture was stirred at room temperature for 1 hour, followed by the rapid addition of the 4-(2, 6-dichlorophenyl)-3-buten-2-one (32.3 g, 0.151 moles) in one portion. The reaction was then stirred for 10 minutes at ambient temperature, then poured into 200 mls of ice water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mls of water, 100mls of brine, dried over anhydrous MgS04, filtered through 2"of silica gel, and concentrated in vacuuo on a rotary evaporator to afford 31.7 g of a thick pale yellow oil which was chromatographed on silica gel with 90% hexane, 10% ethyl acetate. The pure fractions were combined and concentrated in vacuuo on a rotary evaporator to afford 27.9 g of trans-1-(2, 6 dichlorophenyl)-2-acetyl- cyclopropane as a free flowing pale yellow liquid. in 81% yield.

NMR 300 MHz IH CDCl3 1.4-1.48 (m, 1H); 1.78-1.86 (m, 1H) ; 2.21-2.30 (m, 1H) ; 2.34-2.4 (m, 1H) ; 2.41 (s, 3H), 7.2 (m, 1H), 7.3 (d, 2H).

Preparation of E and Z imine isomers: (E. E) and (Z, E) Methyl 2-r2- (Ytrans-l- (2- (2', 6'-dichlorophenvDcyclopropvl) ethylidene) aminooxymethvl) phenyl]-2- methoxyiminoacetate To a 100 ml round bottom flask equipped with magnetic stirrer were charged 1.0 g (0.0044 moles) of the trans-1-(2, 6 dichlorophenyl)-2-acetyl- cyclopropane, 1. 1 g (0.0044 moles) of the methyl (E)-2- (aminooxymethyl) phenyl glyoxylate O-methyloxime, and 50 mls of anhydrous methanol. The reaction was stirred overnight at room temperature. Analysis of an aliquot by GC indicated no starting material and two new products. The reaction was then poured into 100 mls of water and extracted with 3 x 50 ml of ethyl ether. The ether extract was washed with 100 mls of water, 100 mls of 0. 1N HCl, and 100mls of brine, dried over anhydrous magnesium sulfate, filtered, and concentrated in vacuuo on a rotary evaporator to afford 2. Og of a thick yellow oil which was chromatographed on silica with 20 % ethyl acetate/80% hexane. The pure fractions were combined and concentrated in vacuuo on a rotary evaporator to afford 1.4 g of the methyl 2- [2- ( (trans-l- (2- (2', 6'-dichlorophenyl) cyclopropyl)- ethylidene) aminooxymethyl) phenyl]-2-methoxyiminoacetate as a pale yellow oil as a 90/10 A: B (E, E: E, Z) isomer ratio in 72% isolated yield.

NMR 300 MHz 1H CDC13 1.3 (m, 1H) ; 1.7 (m, 1H) ; 1.85 (s, 3H); 1.95 (m, 1H); 2.2 (m, 1H); 3.85 (s, 3H), 4.1 (s, 3H); 5.0 (s, 2H); 7.1 (m, 1H), 7.2 (m, 1H) ; 7.3 (d, 2H); 7.4-7.6 (m, 3H).

An additional 10. Og of the crude product as an orange oil (85% chemically pure and 2: 1 A: B isomers) was chromatographed on silica with 20 % ethyl acetate/80% hexane. 5.02 grams of isomer A as a pale yellow oil was collected (E: E)- methyl 2- [2-((trans-1-(2-(2', 6'-dichlorophenyl) cyclopropyl) ethylidene)- aminooxymethyl) phenyl]-2-methoxyiminoacetate. Compound 6A, Isomer A, E imine, NMR (300MHz., 1H CDCl3) : 1.19-1.30 (1H, m), 1.50-1.58 (1H, m), 1.75- 1.85 (1H, m) 1.84 (3H, s), 2.06-2.14 (1H, m), 3.85 (3H, s), 4.05 (3H, s), 4.98 (2H, s), 7.03-7.49 (7H, m). 0.825 grams of isomer B as a pale yellow oil was collected (E: Z)-methyl 2- [2- ((trans-1-(2-(2', 6'-dichlorophenyl) cyclopropyl) ethylidene)- aminooxymethyl) phenyl]-2-methoxyiminoacetate. Compound 8. 16B, Isomer B, Z imine, NMR (300MHz., 1H CDC13) : 1.21-1.28 (1H, m), 1.40-1.52 (1H, m), 1.70 (3H, s), 2.18-2.23 (1H, m) 2.61-2.70 (1H, m), 3.80 (3H, s), 4.00 (3H, s), 4.97 (2H, s), 7.05-7.52 (7H, m).

Preparation of methyl (E)-2-(aminooxymethyl) phenvl glvoxylate O-methvloxime Methyl (E)-2-O-phthalimidoxymethvl) phenyl glyoxvlate O-methyloxime To a dry 500 ml round bottom flask equipped with magnetic stirrer, and nitrogen inlet were charged 5.1 g (0.0315 moles) of N-hydroxyphthalimide, 1.3 g (0.0315 moles) of sodium hydroxide, and 300 ml of anhydrous dimethylformamide. The dark red solution was stirred at ambient temperature for 20 min., followed by the addition of the methyl 2- (bromomethyl)- phenylglyoxylate-O-methyloxime (15 g, 60% pure, 0.0315 moles) in one portion.

The reaction was stirred at ambient temperature over the weekend, then poured into 800 mls of water and stirred for 1 hour to afford a white solid which was collected by vacuum filtration and washed with water, hexane, and dried under vacuum at 40°C overnight. Isolated 11.5g of a white solid (98% isolated yield) which was consistent with the desired product, methyl (E)-2- (O- phthalimidoxymethyl) phenyl glyoxylate O-methyloxime, upon analysis by 300 MHz 1H NMR (300 MHz, 1H, CDCl3, TMS=0 ppm) 3.8 (s, 3H), 3.95 (s, 3H), 5.0 (s, 2H), 7.1 (d, 1H), 7.5 (m, 2H), 7.7-7.9 (m, 5H).

Preparation of methyl (E)-2- (aminooxymethyl) phenvl glvoxylate O-methvloxime.

To a 250ml round-bottom flask equipped with magnetic stirrer were charged 11.4 g (0.031 moles) of methyl (E)-2- (O-phthalimidoxymethyl) phenyl glyoxylate O-methyloxime 100 mls of anhydrous methanol, and 1.9 g (0.034 moles) of hydrazine monohydrate. The flask was stoppered, and the reaction was stirred at ambient temperature for 2 hours. The resulting solid was removed by filtration and the filtrate was concentrated on the rotary evaporator. The residue was dissolved in 100 mls of ether, filtered, and stripped to afford 7.4 g of a thick yellow oil (100% isolated yield). which was consistent with the desired product methyl (E)-2- (aminooxymethyl) phenyl glyoxylate O-methyloxime upon analysis by 300 MHz 1H NMR. Stored at-20°C until needed for future synthesis.

NMR (300 MHz, 1H, CDCl3, TMS=0 ppm) 3.87 (s, 3H), 4.03 (s, 3H), 4.6 (s, 2H), 4.9-5.4 (bs, 2H), 7.2 (m, 1H), 7.4-7.5 (m, 3H).

Example 2 Preparation of E and Z imine isomers: (E, E) and (Z, E)-N-Methyl 2- [2- ( (trans-1- (2- (2', 6'-dichlorophenyl) cyclopropyl) ethylidene)- aminooxymethyl) phenvll-2-methoxyiminoacetamide Compounds 9.16,9.16A, 9.16B of Table 9.

To a 100 ml flask equipped with magnetic stirrer and were charged 0.7 g (0.00115 moles) of (E, E: Z, E)-methyl 2-[2-((trans-1-(2-(2', 6'- dichlorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetate, 50 mls of methanol, and 2 mls (0.026 moles) of 40% aqueous methyl amine solution. The mixture stirred at ambient temperature overnight. then poured into 200 mls of water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mls of water, 100 mls of 0.1 N HCl, and 100mls of brine, dried over anhydrous MgSO4, filtered, and concentrated in vacuuo on a rotary evaporator to afford 0.6g of N-Methyl 2- [2- ((trans-1-(2-(2', 6'-dichlorophenyl) cyclopropyl) ethylidene) aminooxymethyl)- phenyl]-2-methoxyiminoacetamide as a thick viscous pale yellow oil. 90/10 A: B (E, E: Z, E) isomers ratio in 88% isolated yield.

NMR 300 MHz, lH CDCl3 1.2 (m, 1H) ; 1.6 (m, 1H); 1.8 (s, 3H); 1.9 (m, 1H); 2.2 (m, 1H) ; 2.9 (d, 3H); 3.95 (s, 3H), 5.0 (s, 2H); 6.7 (bs, 1H); 7.1 (m, 1H), 7.2 (m, 1H) ; 7.3 (d, 2H); 7.4-7.6 (m, 3H).

Additionally each of 8. 16A and 8. 16B oxime esters was separately treated as above with methylamine.

Aminolysis of 5.01 grams of 8.16A (E, E isomer) gave 5.02 grams (100% yield) of (E, E)-N-methyl 2-[2-((trans-1-(2-(2', 6'- dichlorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetamide as an oil. The oil was treated with ether, concentrated and cooled in dry ice followed by the addition of hexane to complete the crystallization. The resulting crystals were flitered to give a solid mpt. 94-97oC.

Compound 9.16A, Isomer A, E, E isomer, NMR (300MHz, 1H -Cl3) : 1.20-1.30 (1H, m), 1.51-1.58 (1H, m), 1.80-1.89 (1H, m), 1.82 (3H, s), 2.2 (lH, m), 2.89 (3H, d), 3.96 (3H, s), 4.98 (2H, s), 6.70 (1H, br), 7.05-7.48 (7H, m) : Aminolysis of 0. 825grams of 8. 16B (Z, E isomer) gave 0.825 grams (100% yield) of (Z, E)-N-methyl 2- [2- ( (trans-l- (2- (2', 6'- dichlorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetamide as solid, mpt. 140-146°C. Compound 9.16B, Isomer B, Z, E isomer, NMR (300MHz, 1H -Cl3) :): 1.22-1.30 (1H, m), 1.40-1.51 (1H, m), 1.70 (3H, s), 2.15-2.23 (1H, m), 2.60-2.69 (lH, m), 2.85 (3H, d), 3.90 (3H, s), 4.97 (2H, s), 6.70 (1H, br), 7.09-7.51 (7H, m).

Example 3 <BR> <BR> <BR> <BR> Preparation of E and Z imine isomers: (E, E) and (Z, E) Methyl 2- [2-<BR> <BR> <BR> <BR> <BR> ((trans-1-(2-(2'*6'- difluorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl1-2- methoxyiminoacetate Compound 8.22 of Table 8 Preparation of 4- (2, 6-difluorophenvl)-3-buten-2-one To a 100ml reaction bottle equipped with magnetic stir bar were charged 5. Og (35.2mmole) 2,6-difluorobenzaldehyde in 20 ml acetone, added 50% NaOH (42 mmole) in 60ml water (exothermic) and stirred room temperature. The reaction was monitored by GLC and after 2 hours worked up. The reaction mixture was extracted with 50ml CHCl3, washed with 50ml H20, dried over anhydrous MgS04, filtered, and removed solvent in vacuuo on a rotary evaporator to afford 5.7g of 4- (2, 6-difluoro-phenyl)-3-buten-2-one as a yellow oil (81% purity by GC) in 89.5% isolated yield.

NMR (300 MHz 1H CDCl3) : 2.4 (s, 3H); 6.9 (m, 3H); 7.3 (m, 1H) ; 7.6 (d, 1H).

Preparation of trans-1-(2 6 difluorophenyl)-2-acetyl-cvclopropane To a 500 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel was charged 2.47 g (11.2 mmoles) of trimethyl sulfoxonium iodide, 0.448g (11.2mmole) of powdered sodium hydroxide, and 50 mls DMSO. The mixture was stirred at room temperature for 0.5 hour, followed by the rapid addition of 2. 04g (11.2mmole) 2,6-difluoro-phenyl-3-buten-2-one in 25ml DMSO in one portion. The reaction was stirred for 15 minutes at ambient temperature, poured into 200 mls of ice water, and then extracted with 150 ml of ethyl ether. The ether extract was washed with 4 x 100 mls of water, dried over anhydrous MgSO4, filtered, and concentrated in vacuuo on a rotary evaporator to afford 1.3 g crude product as a yellow oil. This was combined with 1.6g from a similar reaction and the total crude of 2. 9g was chromatographed on silica with CH2Cl2. Fractions (#5-9) were combined and concentrated in vacuuo on a rotary evaporator to afford 1.5g (92% purity by GC) of trans-1-(2, 6 difluorophenyl)-2- acetylcyclopropane as a free flowing pale yellow liquid. in 28. 8% yield.

NMR (300 MHz 1H CDCl3) : 1.6 (m, 2H); 2.3 (s, 3H); 2.4 (m, 2H); 6.8 (m, 2H), 7.1 (m, 1H).

Preparation of E and Z imine isomers: (E, E) and (Z, E) Methyl 2-[2-((trans-1-(2- (2', 6'-difluorophenvl) cyclopropvl) ethylidene) aminooxmethvl) phenyl]-2- methoxvimino acetate To a 25ml reaction vial equipped with magnetic stirrer were charged 1.0 g (0.0051 moles) of the trans-1-(2, 6 difluorophenyl)-2-acetyl-cyclopropane and 1.33 g (0.0056 moles) of the methyl (E)-2- (aminooxymethyl) phenyl glyoxylate O- methyloxime in 5 mls of anhydrous methanol and 5 drops glacial acetic acid.

The reaction was stirred 4 hours at room temperature with formation of precipitate. The sample was refrigerated overnight and then worked up. The white precipitate was filtered in vacuuo, washed with 2 x 10ml hexane, and dried in the vacuum oven at ambient to afford l. lg of the methyl 2-[2-((trans-1- (2- (2', 6'-difluorophenyl) cyclopropyl) ethylidene) aminooxy- methyl) phenyl]-2-methoxyiminoacetate as a white solid, mpt. 81-88°C, as a 79: 21 A: B (E: E, Z: E) isomer ratio in 51.9% isolated yield.

NMR (300 MHz IH CDC13) : 1.4 (t, 2H); 1.65-1.8 (d, 3H); 2.1 (m, 2H); 3.8 (d, 3H); 4.0 (d, 3H); 5.0 (s, 2H); 6.8 (m, 2H), 7-7.2 (m, 2H); 7.3-7.5 (m, 3H).

Example 4 Preparation of E and Z imine isomers: (E, ! and (Z*E !-N-Methyl 2-[2- ((trans-1-(2-(2'*6'- difluorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxviminoacetamide Compounds 9.22A, 9.22B of Table 9.

To a 25ml reaction test tube under nitrogen atmosphere were charged 0.95g of (E, E: Z, E)-methyl 2-[2-((trans-1-(2-(2', 6'- difluorophenyl) cyclopropyl) ethylidene)- aminooxymethyl) phenyl]-2- methoxyiminoacetate (2.3mmole) in 7ml MeOH and 1. 8g 40% aqueous methyl amine (23mmole) which was heated at 55-60C. The reaction was monitored by TLC and worked up after 1.5 hours. Removed the methanol in vacuuo on the rotary evaporator at 300C. To the residue was added 125ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 2 x 50ml water, dried over anhydrous MgS04, filtered, and concentrated in vacuuo on the rotary evaporator at 400C to give lg of (E, E: Z, E)-N-methyl 2-[2-((trans-1-(2-(2', 6'- difluorophenyl) cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2-methoxyimino- acetamide as a 76: 24 A: B (E, E: Z, E) isomer ratio. This mixture was chromatographed on silica with 1: 2 ethyl acetate: hexane to afford both (E, E) and (Z, E) isomers of the N-methyl 2-[2-((trans-1-(2-(2', 6'difluorophenyl)- cyclopropyl) ethylidene) aminooxy-methyl) phenyl]-2-methoxyiminoacetamide.

700mg of isomer-A (E, E) was isolated as a clear oil and 150mg isomer B (Z, E) was isolated also as a pale yellow oil. The chromatrographed combined isolated yield was 89. 5%. Compound 9.7A, Isomer A, E, E isomer: NMR (300 MHz 1H CDC13) 1.4 (t, 2H); 1.8 (s, 3H); 2.1 (m, 2H); 2.9 (d, 3H); 3.9 (s, 3H); 4.9 (s, 2H); 6.7 (bs, 1H) ; 6.8 (t, 2H); 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). Compound 9.7B, Isomer B, Z, E isomer NMR (300 MHz 1H CDC13) 1.3 (m, 1H) ; 1.6 (m, 4H); 2.1 (m, 1H) ; 2.8 (m, 4H); 3.9 (s, 3H); 4.9 (s, 2H); 6.7 (bs, 1H) ; 6.8 (t, 2H); 7-7.2 (m, 2H) ; 7.3-7.5 (m, 3H).

Example 5 Preparation of Methyl [2- (1- (4'-chlorophenvl)-2- methylcyclopropyl)- ethylidene) aminooxymethyl) phenyll-2-methoxyiminoacetate Compound 2.14A of Table 2.

Preparation of E and Z enone isomers of 4- (4-chlorophenyl)-3-penten-2-one To a 500 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged lOg (0.065 moles) of 4'- chloroacetophenone, 10.2g (0.065 moles) of ethyl-trans-3-ethoxycrotonate, and 150 mls of dry dimethylformamide. To this solution was then added 7.3 g (0.065 moles) of potassium t-butoxide in one portion. The reaction was stirred at ambient temperature under nitrogen for a total of three days. The reaction mixture was then poured into 200 mls of water and the aqueous was extracted with 3 x 50 mls of ethyl ether to remove any unreacted starting material. The aqueous fraction was acidified to pH 2 with 1 N aqueous HCl, and extracted with 3 x 100 mls of ethyl ether. The ether extract was washed with 2 x 100 mls of water and 100 mls of saturated sodium chloride solution, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator to afford 12.4 g of a tan solid. This solid was then stirred in 50 mls of conc. HCl for 2 hours at ambient temperature, then poured into 100 g of crushed ice, and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mls of water, 100mls of brine, dried over anhydrous magnesium sulfate, filtered, and concentrated on a rotary evaporator to afford 7.6 g of a yellow liquid, 4- (4-chlorophenyl)-3-penten-2-one, which appeared to be a mixture of the E and Z enones, with some minor chemical impurities, in 59.3 % crude yield.

The product was used in the next step without further purification.

300 MHz 1H NMR (tms=0 ppm) 2.3 (s, 3H); 2.5 (s, 3H); 6.5 (s, 1H) ; 7.3-7.5 (m, 4H).

Preparation of trans and cis-1-(4-chlorophenvl)-1-methyl-2-acetylcsclopropane To a 250 ml round bottom flask equipped with magnetic stirrer, nitrogen inlet and addition funnel were charged the trimethyl sulfoxonium iodide (8.5 g, 0.0386 moles), powdered sodium hydroxide (1.6 g, 0.0386 moles) and 100 mls of dry DMSO. The mixture was stirred at room temperature for 1 hour, followed by the rapid addition of the (E >Z)-4- (4-chlorophenyl)-3-penten-2-one (7.5 g, 0.0386 moles)) in 10 mls DMSO. The reaction was stirred for 3 days at ambient temperature, then poured into 200 mls of ice water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mls of water, 100mls of brine, dried over anhydrous MgS04, filtered through 2"of silica gel, and concentrated on a rotary evaporator to afford 3.2 g of a thick pale yellow oil which was chromatographed on silica gel with 10 % ethyl acetate, 90% hexane.

The pure fractions were combined and concentrated on the rotary evaporator to afford 1.4 g (17.2% isolated yield) of a pale yellow liquid which was consistent with trans and cis-l- (4-chlorophenyl)-1-methyl-2-acetylcyclopropane upon analysis by 300Mz 1H NMR.

300 MHz 1H NMR (tms=0 ppm) 1.2 (m, 1H) ; 1.4 (s, 3H); 1.6 (m, 1H); 2.2 (m, 1H); 2.35 (s, 3H); 7.1-7.4 (m, 4H).

Preparation of Methyl 2- [2- ( (l- (2- (4'-chlorophenyl)-2-methylcyclopropyl)- ethylidene ? aminooxymethvnphenyll-2-methoxyiminoacetate To a 20 ml glass vial equipped with magnetic stirrer were charged the 1.0 g (0.0048 moles) of the trans and cis-1- (4-chlorophenyl)- 1-methyl-2- acetylcyclopropane, 1.2 g (0.0048 moles) of the methyl (E)-2- (aminooxymethyl) phenyl glyoxylate O-methyloxime, and 10 mls of dry methanol.

The vial was capped, and stirred overnight at ambient temperature. The reaction mixture was then poured into 100 mls of water and extracted with 3 x 100 ml of ethyl ether. The ether extract was washed with 2 x 100 mls of water, 100mls of 1 N HCl, and 100mls of saturated sodium chloride solution, dried over anhydrous MgSO4, filtered, and concentrated on a rotary evaporator to afford 1.6 g of a thick orange oil which was chromatographed on silica gel with 20% ethyl acetate, 80% hexane. The pure fractions after chromatography were combined and concentrated on a rotary evaporator to afford 0.75 g of a clear colorless viscous oil (36.5% isolated yield) which was consistent with isomer A, (E, E)- methyl 2- [2- ( (l- (2- (4'-chlorophenyl)-2-methylcyclopropyl) ethylidene) aminooxymethyl) phenyl]-2-methoxyiminoacetate upon analysis by 300 MHz IH NMR with a 70: 30 ratio of cyclopropane isomers.

300 MHz 1H NMR (tms=0 ppm) 1.15 (s, 3H) 1.2 (m, 1H); 1.4 (m, 1H) ; 1.6 (m, 1H) ; 2.0 (s, 3H); 3.85 (s, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 7.1-7.3 (m, 5H) ; 7. 35-7.6 (m, 3H) Example 6 Preparation of (E, !-N-Methyl 2- !-2-methyl cvclopropyl)-ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetamide Compound 3.14A of Table 3.

To a 100 ml round bottom flask equipped with magnetic stirrer were charged 0. 7 g (0.00163 moles) of the (E, E)-methyl 2- [2- ( (l- (2- (4'-dichlorophenyl)- 2-methylcyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetate, 25mls of anhydrous methanol, and 1 ml (0. 0129 moles) of 40% methyl amine in water. The flask was stoppered, and stirred overnight at ambient temperature. The reaction mixture was then poured into 100 mls of water and extracted with 3 x 50 ml of ethyl ether. The ether extract was washed with 2 x 50 mls of water, 50 mls of 1 N HC1, 50mls of saturated sodium chloride solution, dried over anhydrous MgS04, filtered, and concentrated on a rotary evaporator to afford 0.7 g of a yellow viscous oil which was chromatographed on silica gel with 20% ethyl acetate, 80% hexane. The pure fractions were combined and concentrated on a rotary evaporator to afford 0.55 g of a clear colorless viscous oil (79% isolated yield) which was consistent with isomer A (E, E)-N- methyl 2- [2- ( (I- (2- (T-chlorophenyl)-2-methylcyclopropyl) ethylidene) aminooxymethyl) phenyl]-2-methoxyiminoacetamide upon analysis by 300Mz 1H NMR and as 70: 30 mixture of cyclopropane isomers 300 MHz 1H NMR (tms=0 ppm) 1.15 (s, 3H) 1.2 (m, 1H) ; 1.4 (m, 1H) ; 1.65 (m, 1H); 2.0 (s, 3H); 2.9 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H).

Example 7 Preparation of Methyl 2-f2- ( (trans-l- (2-phenyl-2-methylcyclopropyl) ethylidene ! aminooxymethyl ! phenyll-2-methoxyiminoacetate Compound 2.11 of Table 2.

To a 25ml reaction vial equipped with magnetic stirrer were charged 217mg (1.25 mmole) of the trans-1-phenyl-1-methyl-2-acetylcyclopropane and 298 mg (1.25 mmole) of the methyl (E)-2- (aminooxymethyl) phenyl glyoxylate O- methyloxime in 5 ml of anhydrous methanol and 1 drop glacial acetic acid. The reaction was monitored by GC and after 3 hours 90mg more of the methyl 2- (bromomethyl) phenyl glyoxylate O-methyloxime was added and 5 drops of glacial acetic acid. After stirring 20 hours no more starting material ketone remained and the reaction was worked up. The methanol was removed in vacuuo on the rotary evaporator. To the residue was added 100ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 3 x 50ml water, dried over anhydrous MgS04, filtered and concentrated in vacuuo on the rotary evaporator to give 0.6g of yellow oil with solid which was chromatographed on silica with 30: 70 ethyl acetate: hexane. The pure fractions were combined to afford 260mg of a clear oil (isolated yield 52.8%) whose NMR was consistent with methyl 2- [2-((trans-1-(2-phenyl-2-methyl- cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2-methoxyiminoacetate as a mixture of isomers, A>B.

NMR (300 MHz 1H CDC13) : 1.1-1.4 (m, 5H); 1.75 (m, 1H) ; 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.1-7.5 (m, 9H).

Example 8 Preparation of (E, E and ZE)-N-Methyl 2-[2-((trans-1-(2-phenyl-2- methyl-cyclopropyl) ethylidene) aminooxymethvl) phenyl]-2- methoxyiminoacetamide Compound 3.11 of Table 3.

To a 25ml reaction test tube under nitrogen atmosphere were charged 160 mg of the methyl 2-[2-((trans-1-(2-phenyl-2-methyl- cyclopropyl) ethylidene) aminooxy-methyl) phenyl]-2-methoxyiminoacetate (0.41 mmole) in 3ml MeOH and 315 mg 40% aqueous methyl amine (4.1 mmole) which was heated at 55-60C. Monitored by TLC and worked up after 1.5 hours.

Removed the methanol in vacuuo on the rotary evaporator at 30C. To the residue was added 125ml ethyl acetate and 50ml water, partitioned, further washed the organic phase with 2 x 50ml water, dried over anhydrous MgS04, filtered and concentrated in vacuuo on the rotary evaporator at 40C to afford 130 mg (isolated yield 80. 7%) of (E, E and Z, E)-N-methyl 2-[2-((trans-1-(2-phenyl-2- methyl-cyclopropyl) ethylidene) aminooxymethyl) phenyl]-2- methoxyiminoacetamide as a clear oil in a 4: 1 ratio of isomers A to B (E, E: Z, E).

NMR (300 MHz 1H CDC13) : 1. 1-1. 4 (m, 5H); 1.75 (m, 1H); 1.95 (s, 3H); 2.9 (d, 3H); 3.95 (s, 3H); 5.0 (s, 2H); 6.7 (bs, 1H); 7.1-7.5 (m, 9H).

Proton NMR data (300MHz) are provided in Table 13 for typical examples of Tables 1 to 12 and are illustrative of the present invention* Table 13 Compd NMR DATA 2.11 1.1-1.4 (m, 5H); 1.75 (m, 1H); 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5. 0 (s, 2H); 7.1-7.5 (m, 9H). 2.12 1. 1 (m, 1H); 1.2 (s, 3H); 1.4 (m, 1H); 1.7 (m, 1H) ; 2.1 (s, 3H); 3.86 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.0-7.6 (m, 8H) 2.14A 1.15 (s, 3H), 1.2 (m, lH), 1.4 (m, lH) ; 1.6 (m, 1H); 2.0 (s, 3H); 3.85 (s, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H). 2.17 1. 1 (m, 1H) ; 1.2 (s, 3H); 1.4 (m, 1H) ; 1.8 (m, 1H) ; 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.1-7.5 (m, 8H) 2.18A 1.05 (m, 1H); 1.15 (s, 3H); 1.3 (m, 1H); 1.7 (m, 1H); 2.05 (s, 3H); 3.86 (s, 3H); 4.05 (s, 3H); 4.99 (s, 2H); 6.9-7.5 (m, 8H). 2.20 1. 1 (m, 1H); 1.2 (s, 3H); 1.35 (m, 1H) ; 1. 8 (m, 1H); 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.0 (t, 2H); 7.1-7.4 (m, 6H). 2.20B 0.95 (m, 1H) ; 1.2 (s, 3H); 1.85 (s, 3H); 1.9-2.1 (m, 2H); 3.75 (s, 3H); 3.95 (s, 3H); 5.0 (s, 2H); 6.9 (t, 2H); 7.1-7.5 (m, 6H). 2.34 l. l (m, 1H); 1.15 (s, 3H); 1.4 (m, 1H) ; 1.7 (m, 1H); 2.07 (s, 3H); 3.87 (s, 3H); 4.05 (s, 3H); 4.98 (s, 2H); 7.1-7.5 (m, 7H). 2.166 0.8 (m, 3H); 1. 1 (m, 1H) ; 1.2 (m, 2H); 1.4 (m, 1H) ; 1.8 (m, 1H) ; 2.05 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.1-7.4 (m, 9H). 2.170 0.69 (t, 3H); 1.05 (m, 1H); 1.3 (m, 2H); 1.5-1.7 (m, 2H); 2.02 (s, 3H); 3.87 (s, 3H); 4.05 (s, 3H); 4.98 (s, 2H); 6.9-7.5 (m, 8H) 2.178 0.85 (m, 3H); 1. 1-1. 4 (m, 4H); 1.6 (m, 3H); 2.0 (s, 3H); 3.85 (s, 3H); 4.05 (s, 3H); 5.0 (s, 2H); 7.1-7.4 (m, 9H). 2. 189 0.8 (d, 6H); 0.95 (s, 4H); 1.25 (s, 4H); 1.35 (m, 1H) ; 1.9 (m, 1H); 3.8 (s, 3H); 4.0 (s, 3H); 4.9 (q, 2H); 7.1-7.4 (m, 9H). 2.217 1.05 (m, 1H); 1.15 (s, 3H); 1.4 (m, 1H) ; 1.7 (m, 1H) ; 2.07 (s, 3H); 3.86 (s, 3H); 4.05 (s, 3H) ; 4.98 (s, 2H); 6.9-7.6 (m, 7H). 3.11 1.1-1.4 (m, 5H); 1.75 (m, 1H); 1.95 (s, 3H); 2.9 (d, 3H); 3.95 (s, 3H); 5.0 (s, 2H) ; 6.7 (bs, 1H) ; 7.1-7.5 (m, 9H). 3.12A 1. 1 (m, 1H); 1.18 (s, 3H); 1.4 (m, 1H) ; 1.7 (m, 1H); 2.1 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 5.0 (s, 2H); 6.75 (b, 1H); 7.1-7.5 (m, 8H) 3.14A 1.15 (s, 3H) 1.2 (m, 1H) ; 1.4 (m, 1H) ; 1.65 (m, 1H) ; 2.0 (s, 3H); 2.9 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H); 7.1-7.3 (m, 5H); 7.35-7.6 (m, 3H). 3.17 1. 1 (m, 1H) ; 1.2 (s, 3H); 1.3 (m, 1H); 1.7 (m, 1H) ; 2.0 (s, 3H); 2.9 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H) ; 7.1-7.5 (m, 8H). 3.18A 1. 1 (m, 1H) ; 1.15 (s, 3H); 1.35 (m, 1H) ; 1.7 (m, 1H); 2.05 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 4.99 (s, 2H); 6.75 (b, 1H); 6.9-7.5 (m, 8H). 3.20 1. 1 (m, 1H); 1.2 (s, 3H); 1.3 (m, 1H); 1.7 (m, 1H) ; 2.0 (s, 3H); 2.95 (d, 3H); 4. 0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H) ; 7.0 (t, 2H); 7.1-7.5 (m, 6H). 3.20B 0. 95 (m, 1H); 1.2 (s, 3H); 1.9 (s, 3H); 2.0-2.2 (m, 2H); 2.85 (d, 3H); 3.9 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H) ; 6.9 (t, 2H); 7.1-7.5 (m, 6H) 3.34A 1.0 (m, 1H); 1.15 (s, 3H); 1.4 (m, 1H); 1.7 (m, 1H); 2.07 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 4.98 (s, 2H); 6.75 (b, 1H) ; 7.1-7.5 (m, 7H) 3.40A 1.05 (m, 1H) ; 1.12 (s, 3H); 1.3 (m, 1H) ; 1.65 (m, 1H); 2.03 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 4.98 (s, 2H); 6.77 (m, 3H); 7.1-7.5 (m, 5H) 3.166 0.8 (m, 3H); 1. 1 (m, 1H); 1.2 (m, 2H); 1.4-1.7 (m, 2H); 2.1 (s, 3H); 2.85 (d, 3H); 4.1 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H); 7.1-7.4 (m, 9H) 3.170A 0.69 (t, 3H); 1.05 (m, 1H) ; 1.25 (m, 2H); 1.5-1.7 (m, 2H); 2.02 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 4.98 (s, 2H); 6.75 (b, 1H); 6.9-7.5 (m, 8H) 3.178 0.85 (m, 3H); 1. 1-1. 4 (m, 4H); 1. 6 (m, 3H); 2.05 (s, 3H); 2.95 (d, 3H); 4.0 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H) ; 7.1-7.4 (m, 9H) 3.189 0.8 (d, 6H); 1.0 (s, 4H); 1.2 (s, 4H); 1.3 (m, 1H) ; 1.9 (m, 1H) ; 2.9 (d, 3H); 4.0 (s, 3H); 4.85 (q, 2H); 6.8 (bs 1H) ; 7.1-7.4 (m, 9H) 3. 217A 1. 05 (m, 1H) ; 1.15 (s, 3H); 1.4 (m, 1H); 1.7 (m, 1H); 2.07 (s, 3H); 2.91 (d, 3H); 3.96 (s, 3H); 4.98 (s, 2H); 6.75 (b, 1H); 6.9-7.6 (m, 7H) 8. 16 1.3 (m, 1H) ; 1.7 (m, 1H) ; 1.85 (s, 3H); 1.95 (m, 1H) ; 2.2 (m, 1H) ; 3.85 (s, 3H), 4.1 (s, 3H); 5.0 (s, 2H); 7.1 (m, 1H), 7.2 (m, 1H); 7.3 (d, 2H); 7.4- 7.6 (m, 3H). 8. 16A 1.19-1.30 (1H, m), 1.50-1.58 (1H, m), 1.75-1.85 (1H, m) 1.84 (3H, s), 2.06-2.14 (1H, m), 3.85 (3H, s), 4.05 (3H, s), 4.98 (2H, s), 7.03-7.49 (7H, m). 8.16B 1.21-1.28 (1H, m), 1.40-1.52 (1H, m), 1. 70 (3H, s), 2.18-2.23 (1H, m) 2.61-2.70 (1H, m), 3.80 (3H, s), 4.00 (3H, s), 4.97 (2H, s), 7.05-7.52 (7H, m). 8. 22 1.4 (t, 2H); 1.65-1.8 (d, 3H); 2.1 (m, 2H); 3.8 (d, 3H); 4.0 (d, 3H); 5.0 (s, 2H); 6.8 (m, 2H), 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). 8. 200 1. 1 (m, 1H); 1.2 (s, 3H); 1.4 (m, 1H); 1.8 (m, 1H); 2.1 (s, 3H); 3.9 (s, 3H); 4.1 (s, 3H); 5.0 (s, 2H); 7.1-7.6 (m, 7H) 9.16 1.2 (m, 1H); 1.6 (m, 1H) ; 1.8 (s, 3H); 1.9 (m, 1H) ; 2.2 (m, 1H) ; 2.9 (d, 3H); 3.95 (s, 3H), 5.0 (s, 2H); 6.7 (bs, 1H); 7.1 (m, 1H), 7.2 (m, 1H) ; 7.3 (d, 2H); 7.4-7.6 (m, 3H). 9.16A 1.20-1.30 (1H, m), 1.51-1.58 (1H, m), 1.80-1.89 (1H, m), 1.82 (3H, s), 2.2 (lH, m), 2.89 (3H, d), 3.96 (3H, s), 4.98 (2H, s), 6.70 (1H, br), 7.05- 7. 48 (7H, m). 9.16B 1.22-1.30 (1H, m), 1.40-1.51 (1H, m), 1.70 (3H, s), 2.15-2.23 (1H, m), 2.60-2.69 (lH, m), 2.85 (3H, d), 3.90 (3H, s), 4.97 (2H, s), 6.70 (1H, br), 7. 09-7.51 (7H, m). 9.22A 1.4 (t, 2H); 1.8 (s, 3H); 2.1 (m, 2H); 2.9 (d, 3H); 3.9 (s, 3H); 4.9 (s, 2H); 6.7 (bs, 1H) ; 6.8 (t, 2H); 7-7.2 (m, 2H) ; 7. 3-7.5 (m, 3H). 9.22B 1. 3 (m, 1H) ; 1.6 (m, 4H); 2.1 (m, 1H); 2.8 (m, 4H); 3.9 (s, 3H); 4.9 (s, 2H); 6.7 (bs, 1H) ; 6.8 (t, 2H); 7-7.2 (m, 2H); 7.3-7.5 (m, 3H). 9.200 1. 1 (m, 1H) ; 1.2 (s, 3H); 1.4 (m, 1H); 1.8 (m, 1H); 2.1 (s, 3H); 2.85 (d, 3H); 3.9 (s, 3H); 5.0 (s, 2H); 6.8 (bs, 1H) ; 7.1-7.5 (m, 7H) *NMR data for compounds designated by A or B are data for one single stereoisomer for R2C=N-O. Compounds without designation are a mixture of stereoisomers and the data provided is for the major isomer.

Example 9 Numerous compounds of this invention were tested for fungicidal activity in vivo against the diseases described below. The compounds were dissolved in a 1: 1 mixture of acetone and methanol and then diluted with a 2: 1: 1 mixture of water, acetone and methanol (by volume) to achieve the appropriate concentration. The solution was sprayed onto the plants and allowed to dry for two hours. Then the plants were inoculated with fungal spores. Each test utilized control plants which were sprayed with the appropriate solvent and inoculated. For these protective tests, the plants were inoculated one day after treating the plants with the compounds of this invention. The remainder of the technique of each of the tests is given below along with the results for various compounds described herein by the Compound # against the various fungi at a dose of 150 grams per hectare or 38 grams per hectare. The results are percent disease control as compared to the untreated check wherein one hundred was rated as complete disease control and zero as no disease control. The application of the test fungal spores to the test plants was as follows: Wheat Leaf Rust (WLR) . Pucci2ia recorzdita (f. sp. tritici) was cultured on 7-day old wheat (cultivar Fielder) over a 12-day period in the greenhouse. Spores were collected from the leaves by settling on aluminum foil. The spores were cleaned by sieving through a 250-micron opening screen and stored dry. The dried spores were used within one month.. A spore suspension was prepared from dry uredia by adding 20 mg (9.5 million spores) per ml of Soltrol oil. The suspension was dispensed into gelatin capsules (0.7 ml capacity) which attach to the oil atomizers. One capsule is used per flat of twenty 2-inch square pots of 7-day old plants, cultivar Fielder.

After waiting for at least 15 minutes for the oil to evaporate from the wheat leaves, the plants were placed in a dark mist chamber (18-20°C and 100% relative humidity) for 24 hours. The plants were then placed in the greenhouse and evaluated after 12 days for disease.

Wheat Leaf Blotch (SNW) Cultures of Septoria 2odorum was maintained on Czapek-Dox V-8 juice agar plates in an incubator at 20OC with alternating periods of 12 hours of light and 12 hours of darkness for 2 weeks. A water suspension of the spores was obtained by shaking the portion of the plate with fungal material in deionized water and filtering through cheesecloth. The spore-containing water suspension was diluted to a spore concentration of 3.0 x 106 spores per ml. The inoculum was dispersed by a DeVilbiss atomizer over one-week old Fielder wheat plants which had been previously sprayed with the fungicide compound. The inoculated plants were placed in a humidity cabinet at 20°C with alternating 12 hours of light and 12 hours of darkness for 7 days. The inoculated seedlings were then moved to a controlled environment room at 20°C for 2 days of incubation.

Disease control values were recorded as percent control.

Wheat Powdery Mildew (WPM) Erysiphe graminis (f. sp. tritici) was cultured on wheat seedlings, cultivar Fielder, in a controlled temperature room at 18°C. Mildew spores were shaken from the culture plants onto 7-day old wheat seedlings which had been previously sprayed with the fungicide compound. The inoculated seedlings were kept in a controlled temperature room at 18°C and subirrigated. The percent disease control was rated 7 days after the inoculation. Disease control values were recorded as percent control.

Cucumber Powdery Mildew (CPM) Sphaerotheca fulginea was maintained on cucumber plants, cultivar Bush Champion, in the greenhouse. Inoculum was prepared by placing five to ten heavily mildewed leaves in a glass jar with 500ml of water containing 1 drop of Tween 80 (polyoxyethylene monooleate) per 100 ml. After shaking the liquid and leaves, the inoculum was filtered through cheese cloth and misted onto the plants with a squirt bottle mister. The spore count was 100,000 spores/ml. The plants were then placed in the greenhouse for infection and incubation. The plants were scored seven days after inoculation. Disease control values were recorded as percent control.

Tomato Late Blight (TLB) Cultures of Phytophthora i7lfestans were maintained on green pea- amended agar for two to three weeks. The spores were washed from the agar with water and dispersed with a DeVilbiss atomizer over the leaves of 3-week old Pixie tomato plants which had been previously treated with compound of the present invention. The inoculated plants were placed in a humidity cabinet at 20°C for 24 hours for infection. The plants were then removed to a controlled environment room at 20°C and 90% humidity. The plants were scored for disease control after five days.

Grape Downy Mildew (GDM) Plasmopara viticola was maintained. leaves of grape plants, cultivar Delaware, in a controlled temperature chamber at 20°C in humid air with moderate light intensity for 7 to 8 days. A water suspension of the spores from infested leaves was obtained and the spore concentration was adjusted to about 3 x 105 per ml of water. Delaware grape plants were inoculated by spraying the underside of leaves with a De Vilbiss atomizer until small drops were observed on the leaves. The inoculated plants were incubated in a mist chamber for 24 hours at 20°C. The plants were then removed to a controlled environmental room at 20°C. Disease control values were recorded as percent control seven days after inoculation.

Rice Blast (RB) Cultures of Pyricularia oyrzae were maintained on potato dextrose agar for two to three week. The spores were washed from the agar with water containing 1 drop of Tween 80 per 100ml. After filtering the spore suspension through two layers of cheese cloth, the spore count was adjusted to 5 x 105 per ml of water. The spore suspension was sprayed onto 12-day old rice plants, cultivar M-1, using a DeVilbiss atomizer. The inoculated plants were placed in a humidity at chamber 20°C for 36 hours to allow for infection.. After the infection period the plants were placed in the greenhouse. After 6 days, the plants were scored for disease control. Disease control values were recorded as percent control.

Cucumber Downy Mildew (CDM) The cultures of Pseudoperonospora cubensis were maintained on cucumber plants. Leaves showing excellent sporulation were frozen in glass jars at-40°C.

After extracting the spores by shaking the leaves in water, the lower surface of the treated cucumber leaves were sprayed with a spore concentration of 100,000 spores per ml of water. The cucumber plants were placed in a Dew Chamber at 20°C for 24 hr. After this infection period, the plants were placed in a growth chamber at 20°C and 90% humidity for 5 days. After severe infection was observed, the leaves were examined for disease development. Disease control values were recorded as percent control.

Cucumber Anthracnose (CA) The fungal pathogen Colletotrichum lagenarium was cultured on potato dextrose agar (PDA) in the dark at 22 C for a period of 8 to 14 days. Spores of C. lagenarium were removed from the PDA plates by flooding the plate surface with distilled water, amended with 0.5% v/w of yeast extract. The upper surface of the fungal colony was scraped with a blunt instrument until most of the spores were released into the aqueous environment. The spore suspension was filtered though cheesecloth, and the spore count was adjusted by adding more water, containing the yeast extract, until 3.0 x 106 spores per ml of water was achieved.

Tomato Early Blight (TEB) Cultures of Alternaria solani were grown on V-8 juice agar plates at room temperature under fluorescent lights (12 hr light, 12 hr dark) for 2 weeks. A suspension of the spores was obtained flooding the surface of the agar plate with a 0.5% solution of yeast extract in distilled water. The surface of the agar plate was scraped lightly with a blunt plastic instrument to release the spores into the liquid. The spore suspension was filtered through cheesecloth, and the spore concentration was adjusted to approximately 80,000 spores per ml. Tomato plants (cv. Patio hybrid) were approximately 18-days old at time of treatment with experimental compounds. Following treatment, the plants were placed in the greenhouse for 1 day. After this period, the plants were inoculated with freshly prepared spore suspension using a DeVilbiss atomizer. The spore suspension was applied to the upper surface of the leaves. After inoculation, the plants were placed in a Dew Chamber at 20°C for 24 hr to allow for infection.

The plants were then transferred to a growth chamber at 22°C and 80% humidity for three days. Disease control values were recorded a percent control.

The chemically-treated cucumber plants were 15-days old, cultivar Bush Champion. The upper leaf surface of the plants were sprayed with the spore suspension until runoff, using a hand-held pump spray bottle. The plants were placed in a fluorescent-lighted mist chamber (12 hr light, 12 hr dark) for 48 hours. After that infection period, the plants were placed in a growth chamber for 3 days at 25 C and 90% humidity. The treated plants were then evaluated for disease control. Disease control values were recorded as percent control.

Wheat Helminthosporium (HEL) The fungal pathogen, Helmarzthosporium sativum (also known as Bipolaris soroMncma), was cultured on V8 agar media at room temperature under fluorescent lights (12 hr on, 12 hr off) for a period of two to four weeks. Spores of H. sativum were removed from the V8 agar plates by flooding the plate surface with distilled water, amended with 0.5% v/w of yeast extract and 1 drop of Tween-80 per 100 ml. The upper surface of the fungal colonies were rubbed lightly with a plastic instrument until most of the spores were released into the aqueous environment. The spore suspension was filtered though cheesecloth, and the spore count was adjusted by adding additional water containing the yeast extract and Tween-80, until a spore count of 60,000 to 80,000 spores per ml was achieved.

Chemically-treated wheat plants were sprayed with the spore suspension until runoff, using a hand-held pump spray bottle. The plants were placed in a fluorescent-lighted mist chamber for 24 hours. After that infection period, the plants were placed in a growth chamber for 1-2 days at 24 °C with 14 hour photoperiod and 20 °C at night. The treated plants were then evaluated for disease control. Disease control values were recorded as percent control.

When tested against wheat leaf rust at 150 grams per hectare compounds 2.11,2.166,3.11,3.14A, 3.166,3.178,9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.12,2.14A, 2.18A, 2.34,2.70, 2.217,3.12A, 3.17,3.18A, 3.20,3.34A, 3.40A, 3. 70A and 9.200 exhibited 95% or better control.

When tested against wheat leaf blotch at 150 grams per hectare compounds 3.11,3.14A, 9.16 and 9.22A exhibited 90% or better control and when tested at 38 grams per hectare compounds 2.11,2.12,2.17,2.18A, 2.166, 2.217,3.12A, 3.17,3.18A, 3.20,3.34A, 3.70A, and 3.217A exhibited 90% or better control.

When tested against wheat powdery mildew at 150 grams per hectare compounds 2.11,2.166,9.16, and 9.22A exhibited 90% or better control and when tested at 38 grams per hectare compounds 2.18A, 2.20,2.70,2.217,3.20, 3.40A, and 3.217A exhibited 90% or better control.

When tested against cucumber powdery mildew at a dose of 150 grams per hectare compounds 3.11,3.14A, 8. 16,9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.18A, 2.34,2.217,3.12,3.17, 3.18A, 3.20,3.34A, 3.40A and 3.217A exhibited 99% or better control.

When tested against tomato late blight at 150 grams per hectare compounds 3.11,3.14A, 8.16,9.16 and 9.22A exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.14A, 2.17,2.18A, 2.20,3.12A, 3.17,3.18A, 3.20,3.40A, 3. 70A and 3.217A exhibited 95% or better control.

When tested against grape downy mildew at 150 grams per hectare compounds 3.11,9.16, and 9.22A exhibited 100% control.

When tested against rice blast at 150 grams per hectare compounds 3.11, 3.14A, 8.16,9.16, and 9.22A exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.12,2.14A, 2.18A, 2.20,2.20B, 3.12A, 3.17, 3.18A, 3.20,3.40A and 3.217A exhibited 90% or better control.

When tested against cucumber downy mildew at 150 grams per hectare compounds 3.11,3.14A and 9.16 exhibited 95% or better control and when tested at 38 grams per hectare compounds 2.14A, 2.17,2.20,3.17 and 3.20 exhibited 90% or better control and when tested at 9 grams per hectare compound 9.22A exhibited 100% control.

When tested against cucumber anthracnose at 150 grams per hectare compounds compounds 3.11,3.14A, 9.16 and 9.22A exhibited 100% control and when tested at 38 grams per hectare compounds 2.12,2.14A, 2.17,2.18A, 2.20, 2.34,2.70,2.166,2.217,3.12A, 3.17,3.18A, 3.20,3.34A, 3.40A, 3.70A, 3.166, 3.178,3.217A, 8. 16,8.200 and 9.200 exhibited 95% or better control.

When tested against tomato early blight at 38 grams per hectare compounds compounds 2.14A, 2.17,2.20,3.11,3.14A, 3.17,3.20,3.166,8.16,9.16 and 9.200. exhibited 95% or better control.

The surprising activity of the compounds of this invention is demonstrated through comparison of these compounds with similarly substituted compounds in tests as described above. The following table provides data for Example compound 9.16 (wherein R7 is 2,6-dichlorophenyl and R6 is hydrogen) in a side- by-side compared to a similar compound wherein R7 is 4-fluorophenyl and R6 is hydrogen (comparison example 1-CE-1) and a compound wherein R7 is 4- chlorophenyl and R6 is hydrogen (CE-2): Dose Compound Dose CA CPM RB SNW TEB WLR WPM 9.16 25 100 100 98 95 95 95 85 9.16 6 99 95 90 95 85 90 0 CE-1 25 99 100 95 80 95 95 80 CE-1 6 85 80 85 75 95 90 80 CE-2 25 90 99 90 95 95 90 50 CE-2 6 80 85 85 85 95 85 0 The following table provides data for Example compound 9.16 (wherein R7 is 2,6-dichlorophenyl and R6 is hydrogen) in a different side-by-side test compared to CE-1 and a similar compound wherein R7 is phenyl and R6 is hydrogen (CE-3): Dose Compound 9/ha CA CPM SNW TEB WLR WPM 9.16 38 99 100 90 100 98 85 9.16 9 98 95 90 95 90 75 9.16 2 85 75 80 80 90 50 9.16 0.5 0 0 0 75 50 0 CE-1 38 75 90 90 85 98 85 CE-1 9 75 75 80 90 85 50 CE-1 2 0 0 50 0 80 0 CE-1 0. 5 0 0 0 0 50 0 CE-3 38 75 50 80 95 85 0 CE-3 9 50 0 50 75 80 0 CE-3 2 0 0 50 0 50 0 CE-3 0. 5 0 0 0 0 0 0 The following table provides data for Example compound 9.16 (wherein R7 is 2,6-dichlorophenyl and R6 is hydrogen and) in another side-by-side test compared to CE-2 (R7 is 4-chlorophenyl and R6 is hydrogen): Dose Compound g/ha CA CDM CPM RB SNW TLB WLR WPM 9.16 38 100 100 100 98 99 100 99 90 9.16 9 95 99 100 95 95 90 99 85 9.16 2 85 100 80 80 95 80 99 50 9.16 0.5 50 75 0 80 90 50 90 0 CE-2 38 85 100 100 95 90 100 100 90 CE-2 9 75 100 90 85 95 100 99 80 CE-2 2 0 100 50 50 80 85 85 50 CE-2 0. 5 0 75 0 0 75 50 75 0 The following table provides data for Example compound 3.11 (wherein R6 is methyl and R7 is phenyl) in a side-by-side test compared to CE-3 (R6 is hydrogen and R7 is phenyl): Compound Dose CA CPM HEL SNW TEB WLR WPM g/ha 3.11 150 95 80 99 100 98 85 3.11 38 99 85 80 95 100 99 75 3. 11 9 98 75 0 85 90 95 50 3. 11 2 90 0 0 80 80 85 0 3.11 0.5 0 0 0 50 0 75 0 CE-3 150 85 85 50 85 100 98 75 CE-3 38 75 50 0 80 95 85 0 CE-3 9 50 0 0 50 75 80 0 CE-3 2 0 0 0 60 0 50 0 CE-3 0. 5 0 0 0 0 0 0 0 The following table provides data for Example compound 3.20 (wherein R6 is methyl and R7 is 4-fluorophenyl) in a side-by-side test compared to CE-1 (wherein Rr, is hydrogen and R7 is 4-fluorophenyl) : Dose Compoundg/ha CA CPM HEL SNW TEB WLR WPM 3.20 150 99 100 85 99 95 100 90 3.20 38 98 90 80 99 95 100 85 3. 20 99 80 80 95 100 99 80 3.20 2 75 50 75 90 80 90 75 3.20 0.5 0 0 0 80 0 80 0 CE-1 150 95 100 75/P 90 98 85 CE-1 38 75 90 50 90 85 98 85 CE-1 9 75 75 0 80 90 85 50 CE-1 2 0 0 0 50 0 80 0 CE-1 0. 5 0 0 0 0 0 50 0 The compounds of this invention are useful as agricultural fungicides and, as such, can be applied to various loci such as the seed, the soil or the foliage of plants to be protected.

The compounds of this invention can be applied as fungicidal sprays by methods commonly employed, such as conventional high-volume hydraulic sprays, low-volume sprays, air-blast spray, aerial sprays and dusts. The dilution and rate of application will depend upon the type of equipment employed, the method of application, plants to be treated and diseases to be controlled.

Generally, the compounds of this invention will be applied in amount of from about 0.005 kilogram to about 50 kilograms per hectare and preferably from about 0.025 to about 25 kilograms per hectare of the active ingredient.

As a seed protectant, the amount of toxicant coated on the seed is usually at a dosage rate of from about 0.05 to about 20, preferably from about 0.05 to about 4, and more preferably from about 0.1 to about 1 grams per hundred kilograms of seed. As a soil fungicide the chemical can be incorporated in the soil or applied to the surface usually at a rate of from about 0.02 to about 20, preferably from about 0.05 to about 10, and more preferably from about 0.1 to about 5 kilograms per hectare. As a foliar fungicide, the toxicant is usually applied to growing plants at a rate of from about 0.01 to about 10, preferably from about 0.02 to 5, and more preferably from about 0.25 to about 1 kilograms per hectare.

Inasmuch as the compounds of this invention display fungicidal activity, these compounds can be combined with other known fungicides to provide broad spectrum activity. Suitable fungicides include, but are not limited to, those compounds listed in U. S. Patent Number 5,252,594 (see in particular columns 14 and 15). Other known fungicides which an be combined with the compounds of this invention are dimethomorph, cymoxanil, thifluzamide, furalaxyl, ofurace, benalaxyl, oxadixyl, propamocarb, cyprofuram, fenpiclonil, fludioxonil, pyrimethanil, cyprodinil, triticonazole, fluquinconazole, metconazole, spiroxamine, carpropamid, azoxystrobin, kresoxim-methyl, metominostrobin and trifloxystrobin.

The compounds of this invention can be advantageously employed in various ways. Since these compounds possess broad spectrum fungicidal activity, they can be employed in the storage of cereal grain. These compounds can also be employed as fungicides in cereals including wheat, barley and rye, in rice, peanuts, beans and grapes, on turf, in fruit, nut and vegetable orchards, and for golf course applications.

Examples of diseases against which the compounds of the invention are useful include helminthosporium of corn and barley, wheat and barley powdery mildew, wheat leaf and stem rusts, barley stripe and leaf rust, tomato early blight, tomato late blight, peanut early leaf spot, grape powdery mildew, grape black rot, apple scab, apple powdery mildew, cucumber powdery mildew, brown rot of fruits, botrytis, bean powdery mildew, cucumber anthracnose, wheat septoria nodorum, rice sheath blight and rice blast Compositions and formulations according to the present invention may also include known pesticidal compounds. This expands the spectrum of activity of the preparation and may give rise to synergism. Suitable insecticides known in the art include those listed in U. S. Patent 5,075,471, see in particular columns 14 and 15.

The compounds of the present invention can be used in the form of compositions or formulations. Examples of the preparation of compositions and formulations can be found in the American Chemical Society publication "Pesticidal Formulation Research," (1969), Advances in Chemistry Series No. 86, written by Wade Van Valkenburg; and the Marcel Dekker, Inc. publication "Pesticide Formulations", (1973) edited by Wade Van Valkenburg. In these compositions and formulations, the active substance is mixed with conventional inert agronomically acceptable (i. e., plant compatible and/or pesticidally inert) pesticide diluents or extenders such as solid carrier material or liquid carrier material, of the type usable in conventional pesticide compositions or formulations. By"agronomically acceptable carrier"is meant any substance which can be used to dissolve, disperse of diffuse the active ingredient in the composition without impairing the active ingredient's effectiveness and which by itself has no significant detrimental effect on the soil, equipment, desirable plants, or agronomic environment. If desired, adjuvants such as surfactants, stabilizers, antifoam agents and anti-drift agents may also be combined.

Examples of compositions and formulations according to the invention are aqueous solutions and dispersions, oily solutions and oil dispersions, pastes, dusting powders, wettable powders, emulsifiable concentrates, flowables, granules, baits, invert emulsions, aerosol compositions and fumigating candles.

Wettable powders, pastes, flowables and emulsifiable concentrates are concentrated preparations which are diluted with water before or during use. In such formulations, the compounds are extended with a liquid or solid carrier and, when desired, suitable surfactants are incorporated. Baits are preparations generally comprising a food or other substance attractive to insects, that includes at least one compound of the instant invention.

It is usually desirable, particularly in the case of foliar spray formulations, to include adjuvants, such as wetting agents, spreading agents, dispersing agents, stickers, adhesive and the like in accordance with agricultural practices.

A listing of such adjuvants commonly used in the art, and a discussion of adjuvants, can be found in many references, such as in the John W. McCutcheon, Inc. publication"Detergents and Emulsifiers, Annual." The active compounds of the present invention may be employed alone or in the form of mixtures with one another and/or with such solid and/or liquid dispersible carrier vehicles and/or with other known compatible active agents, especially plant protection agents, such as other insecticides, arthropodicides, nematicides, fungicides, bactericides, rodenticides, herbicides, fertilizers, growth- regulating agents, synergists.

In the compositions of the invention, the active compound is present in an amount substantially between about 0.0001 (1: 999,999)-99 (99: 1) % by weight.

For compositions suitable for storage or transportation, the amount of active ingredient is preferably between about 0.5 (1: 199)-90 (9: 1) % by weight, and more preferably between about 1 (1: 99)-75 (3: 1) % by weight of the mixture.

Compositions suitable for direct application or field application generally contain the active compound in an amount substantially between about 0.0001 (1: 999,999)-95 (19: 1) %, preferably between about 0.0005 (1: 199,999)-90 (9: 1) % by weight, and more preferably between about 0.001 (1: 99,999)-75 (3: 1) % by weight of the mixture. The composition can also be stated as a ratio of the compound to the carrier. In the present invention the weight ratio of these materials (active compound/carrier) can vary from 99: 1 (99%) to 1: 4 (20%) and more preferably from 10: 1 (91%) to 1: 3 (25%).

In general, the compounds of this invention can be dissolved in certain solvents such as acetone, methanol, ethanol, dimethylformamide, pyridine or dimethyl sulfoxide and such solutions can be diluted with water. The concentrations of the solution can vary from about 1% to about 90% with a preferred range being from about 5% to about 50%.

For the preparation of emulsifiable concentrates, the compound can be dissolved in suitable organic solvents, or a mixture of solvents, together with an emulsifying agent to enhance dispersion of the compound in water. The concentration of the active ingredient in emulsifiable concentrates is usually from about 10% to about 90%, and in flowable emulsion concentrates, can be as high as about 75%.

Wettable powders suitable for spraying, can be prepared by admixing the compound with a finely divided solid, such as clay, inorganic silicate and carbonate, and silica and incorporating wetting agents, sticking agents, and/or dispersing agents in such mixtures. The concentration of active ingredients in such formulations is usually in the range of from about 20% to about 99%, preferably from about 40% to about 75%. A typical wettable powder is made by blending 50 parts of a compound of Formula I, 45 parts of a synthetic precipitated hydrated silicon dioxide and 5 parts of sodium lignosulfonate. In another preparation a kaolin type (Barden) clay is used in place of the synthetic precipitated hydrated silicon dioxide in the above wettable powder, and in another such preparation 25% of the silicon dioxide is replaced with a synthetic sodium silicoaluminate.

Dusts are prepared by mixing compounds of Formula I, or the enantiomorphs, salts and complexes thereof with finely divided inert solids which can be organic or inorganic in nature. Materials useful for this purpose include botanical flours, silicas, silicates, carbonates and clays. One convenient method of preparing a dust is to dilute a wettable powder with a finely divided carrier. Dust concentrates containing from about 20% to about 80% of the active ingredient are commonly made and are subsequently diluted to from about 1% to about 10% use concentration.

In addition to the aforementioned ingredients the preparations according to the invention may also contain other substances commonly used in preparations of this kind. For example, a lubricant, such as calcium stearate or magnesium stearate, may be added to a wettable powder or to a mixture to be granulated. Furthermore there may, for example, be added"adhesives"such as polyvinylalcohol-cellulose derivatives or other colloidal materials, such as casein, to improve the adherence of the pesticide to the surface to be protected.